UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the quarterly period ended September 30, 2026

 

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the transition period from _____________

 

Commission File Number: 001-41750

 

BioNexus Gene Lab Corp.

(Exact name of registrant as specified in its charter)

 

Wyoming

35-2604830

(State or Other Jurisdiction of

 

(I.R.S. Employer

Incorporation or Organization)

 

Identification No.)

 

 

Unit A-28-7, Level 28, Tower A,

Menara UOA Bangsar,

No. 5 Jln Bangsar Utama 1,

Kuala Lumpur, Malaysia

59000

(Address of Principal Executive Offices)

 

(Zip Code)

 

+1 307 241 6898

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, no par value

 

BGLC

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer, “ “ accelerated filer, “ “non-accelerated filer ,” “ smaller reporting company, “ and “ emerging growth company “ in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated Filer

☒

Smaller reporting company

☒

 

 

Emerging growth company

☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

 

As of November 19, 2026, there were 3,493,442 shares of common stock, no par value per share, issued and outstanding.

 

 

 

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION

 

Page

 

Item 1.

Financial Statements

 

4

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

34

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

45

Item 4.

Controls and Procedures

 

46

 

 

 

 

 

 

PART II – OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

47

Item 1A.

Risk Factors

 

47

 

Item 2.

Unregistered Sale of Equity Securities and Use of Proceeds

 

48

Item 3.

Defaults Upon Senior Securities

 

48

Item 4.

Mine Safety Disclosures

 

48

Item 5.

Other Information

 

48

Item 6.

Exhibits

 

49

 

SIGNATURES

 

50

 

 
2

Table of Contents

 

CAUTIONARY NOTE REGARDING

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations and or future financial performance. In some cases, you can identify forward-looking statements by their use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “ought to,” “plan,” “possible,” “potentially,” “predicts,” “project,” “should,” “will,” “would,” negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements relating to:

 

 

·

our goals and strategies;

 

 

 

 

·

our future business development, results of operations and financial condition;

 

 

 

 

·

our estimates regarding expenses, future revenues, capital requirements and our need for additional financing;

 

 

 

 

·

our estimates regarding the market opportunity for our services;

 

 

 

 

·

the impact of government laws and regulations;

 

 

 

 

·

our ability to recruit and retain qualified personnel;

 

 

 

 

·

our failure to comply with regulatory guidelines;

 

 

 

 

·

uncertainty in industry demand;

 

 

 

·

general economic conditions and market conditions in the diagnostics, specialty chemicals and contract development and manufacturing organization (CDMO) industries;

 

 

 

 

·

future sales of large blocks of our securities, which may adversely impact our share price; and

 

 

 

 

·

depth of the trading market in our securities.

 

The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those described in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and elsewhere in this Quarterly Report on Form 10-Q.

 

You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

 

 
3

Table of Contents

 

PART I — FINANCIAL INFORMATION

 

ITEM 1. Financial Statements

 

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

AS OF SEPTEMBER 30, 2026 AND DECEMBER 31, 2025

(Currency expressed in United States Dollars (“US$”)) 

 

 

 

 

As of

 

 

 

Note

 

 

September 30,

 

 

December 31,

 

 

 

 

 

2026

 

 

2025

 

 

 

 

 

(Unaudited)

 

 

(Audited)

 

ASSETS

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

 

 

 

Cash and bank balances

 

 

 

 

 

865,804

 

 

 

2,383,369

 

Fixed deposits placed with financial institutions (including $1,139,737 and $1,553,322 of fixed deposits with original maturities more than three months as of September 30, 2026 and December 31, 2025 respectively)

 

 

 

 

 

2,497,798

 

 

 

1,656,336

 

Trade receivables, net of allowance for credit losses of $773,304 and $703,995 as of September 30, 2026 and December 31, 2025 respectively (including $nil and $31,420 of trade receivables from related party as of September 30, 2026 and December 31, 2025 respectively)

 

 

3

 

 

 

38,142

 

 

 

505,885

 

Other receivables, deposits and prepayments

 

 

 

 

 

 

89,502

 

 

 

81,728

 

Tax recoverable

 

 

4

 

 

 

61,105

 

 

 

61,384

 

Inventories

 

 

 

 

 

 

636,226

 

 

 

676,703

 

Total current assets

 

 

 

 

 

 

4,188,577

 

 

 

5,365,405

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NON-CURRENT ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

Other assets

 

 

5

 

 

 

833,330

 

 

 

83,333

 

Operating lease right-of-use assets

 

 

6

 

 

 

131,017

 

 

 

177,737

 

Finance lease right-of-use assets

 

 

7

 

 

 

69,424

 

 

 

-

 

Property, plant and equipment, net

 

 

8

 

 

 

1,511,930

 

 

 

1,598,769

 

Investments in equity securities

 

 

9

 

 

 

2,026,423

 

 

 

2,027,540

 

Total non-current assets

 

 

 

 

 

 

4,572,124

 

 

 

3,887,379

 

TOTAL ASSETS

 

 

 

 

 

$8,760,701

 

 

$9,252,784

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

 

Trade payables

 

 

10

 

 

 

12,517

 

 

 

2,335

 

Other payables and accrued liabilities (including $504,330 and $83,333 of other payables to related party as of September 30, 2026 and December 31, 2025 respectively)

 

 

11

 

 

 

806,519

 

 

 

401,611

 

Operating lease liabilities

 

 

6

 

 

 

55,506

 

 

 

59,147

 

Finance lease liabilities

 

 

7

 

 

 

6,862

 

 

 

-

 

Advance payment from customer

 

 

 

 

 

 

8,347

 

 

 

8,385

 

Amount owing to directors

 

 

 

 

 

 

230,277

 

 

 

49,479

 

Total current liabilities

 

 

 

 

 

 

1,120,028

 

 

 

520,957

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NON-CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities

 

 

6

 

 

 

75,435

 

 

 

116,899

 

Finance lease liabilities

 

 

7

 

 

 

44,030

 

 

 

-

 

Total non-current liabilities

 

 

 

 

 

 

119,465

 

 

 

116,899

 

TOTAL LIABILITIES

 

 

 

 

 

$1,239,493

 

 

$637,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COMMITMENT AND CONTINGENCIES

 

 

 

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

As at September 30, 2026, common stock, no par value; 300,000,000 shares authorized and 2,933,442 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*.

 

 

15

 

 

$20,974,793

 

 

$20,174,795

 

Additional paid in capital

 

 

 

 

 

 

(5,011,891)

 

 

(5,011,891 )

Accumulated deficit

 

 

 

 

 

 

(8,311,633)

 

 

(6,427,227 )

Accumulated other comprehensive losses

 

 

 

 

 

 

(130,061)

 

 

(120,749 )

TOTAL STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

7,521,208

 

 

 

8,614,928

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

$8,760,701

 

 

$9,252,784

 

* Issued and outstanding shares of common stock have been adjusted as below:

1) for the periods prior to April 7, 2025, to reflect the 1-for-10 reverse stock split effected on that date on a retroactive basis as described in Note 15.

2) for the periods prior to July 20, 2023, to reflect the 1-for-12 reverse stock split effected on that date on a retroactive basis as described in Note 15

 

See accompanying notes to the condensed consolidated financial statements.

 

 
4

Table of Contents

 

PART I — FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

 

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS)

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

 (Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

 

Three-month periods ended

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE (Including $nil and $25,649 of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $57,632 of revenue from related parties for the nine-month period ended September 30, 2026 and

2025, respectively)

 

$47,917

 

 

$2,543,823

 

 

$146,915

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)

 

 

(43,429)

 

 

(2,166,138)

 

 

(130,235)

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

4,488

 

 

 

377,685

 

 

 

16,680

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

-

 

 

 

4,192

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

16,541

 

 

 

20,778

 

 

 

54,903

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

-

 

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Gain from foreign exchange

 

 

4,402

 

 

 

-

 

 

 

10,065

 

 

 

-

 

Others

 

 

6,239

 

 

 

40,414

 

 

 

22,779

 

 

 

147,231

 

TOTAL OTHER INCOME

 

 

27,182

 

 

 

107,760

 

 

 

87,747

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(35,007)

 

 

(551,569)

 

 

(123,762)

 

 

(1,700,691)

Research and development

 

 

(13,578)

 

 

(14,876)

 

 

(41,736)

 

 

(39,572)

General and administrative (Including $nil and $1,065 of rental expenses to related party for the three month period ended September 30, 2026 and 2025, respectively, and $nil and $3,156 of rental expenses to related party for the nine-month period ended September 30, 2026 and 2025, respectively)

 

 

(311,387)

 

 

(448,791)

 

 

(942,942)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

75,721

 

 

 

(175,818)

 

 

(76,814)

 

 

(121,030)

Share-based compensation

 

 

(799,998)

 

 

-

 

 

 

(799,998)

 

 

-

 

TOTAL OPERATING EXPENSES

 

 

(1,084,249)

 

 

(1,191,054)

 

 

(1,985,252)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,052,579)

 

 

(705,609)

 

 

(1,880,825)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,801)

 

 

(3,382)

 

 

(3,581)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(1,054,380)

 

 

(708,991)

 

 

(1,884,406)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(1,054,380)

 

$(708,991)

 

$(1,884,406)

 

$(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive (loss)/income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation (loss)/gain

 

 

(2,852)

 

 

3,216

 

 

 

(9,312)

 

 

442,453

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COMPREHENSIVE LOSS

 

$(1,057,232)

 

$(705,775)

 

$(1,893,718)

 

$(1,506,037)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share - Basic and diluted

 

 

(0.392)

 

 

(0.395)

 

 

(0.751)

 

 

(1.085)

Weighted average number of common shares outstanding, Basic and Diluted #

 

 

2,692,209

 

 

 

1,796,597

 

 

 

2,509,953

 

 

 

1,796,597

 

 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025 and the 1-for-12 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 15.

 

See accompanying notes to the condensed consolidated financial statements

 

 
5

Table of Contents

 

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Amount expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

 

Common stock

 

 

Additional

paid in

 

 

Accumulated

 

 

Accumulated

other

comprehensive

 

 

Total

stockholders’

 

 

 

Number of shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

losses

 

 

equity

 

Balance as of December 31, 2024 *

 

 

1,796,766

 

 

$17,332,315

 

 

$(5,011,891)

 

$(3,442,620)

 

$(555,000)

 

$8,322,804

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(623,327)

 

 

-

 

 

 

(623,327)

Foreign currency translation gain

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

72,159

 

 

 

72,159

 

Balance as of March 31, 2025 *

 

 

1,796,766

 

 

$17,332,315

 

 

$(5,011,891)

 

$(4,065,947)

 

$(482,841)

 

$7,771,636

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(616,172)

 

 

-

 

 

 

(616,172)

Round down shares #

 

 

(169)

 

 

(505)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(505)

Foreign currency translation gain

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

367,078

 

 

 

367,078

 

Balance as of June 30, 2025 *

 

 

1,796,597

 

 

$17,331,810

 

 

$(5,011,891)

 

$(4,682,119)

 

$(115,763)

 

$7,522,037

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(708,991)

 

 

-

 

 

 

(708,991)

Foreign currency translation gain

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,216

 

 

 

3,216

 

Balance as of September 30, 2025 *

 

 

1,796,597

 

 

$17,331,810

 

 

$(5,011,891)

 

$(5,391,110)

 

$(112,547)

 

$6,816,262

 

 

* Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025 and the 1-for-12 reverse stock split effected on July 20, 2023, on a retroactive basis.

 

# Rounding down of 169.30 fractional shares resulting from a 10-to-1 reverse stock split at a price of $2.98 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Common stock

 

 

Additional

paid in

 

 

Accumulated

 

 

other

comprehensive

 

 

Total

stockholders’

 

 

 

Number of shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

losses

 

 

equity

 

Balance as of December 31, 2025 *

 

 

2,417,314

 

 

$20,174,795

 

 

$(5,011,891)

 

$(6,427,227)

 

$(120,749)

 

$8,614,928

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(543,575)

 

 

-

 

 

 

(543,575)

Foreign currency translation gain

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

21,900

 

 

 

21,900

 

Balance as of March 31, 2026 *

 

 

2,417,314

 

 

$20,174,795

 

 

$(5,011,891)

 

$(6,970,802)

 

$(98,849)

 

$8,093,253

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(286,451)

 

 

-

 

 

 

(286,451)

Foreign currency translation loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(28,360)

 

 

(28,360)

Balance as of June 30, 2026 *

 

 

2,417,314

 

 

$20,174,795

 

 

$(5,011,891)

 

$(7,257,253)

 

$(127,209)

 

$7,778,442

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,054,380)

 

 

-

 

 

 

(1,054,380)

Issuance of shares

 

 

516,128

 

 

 

799,998

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

799,998

 

Foreign currency translation loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,852)

 

 

(2,852)

Balance as of September 30, 2026 *

 

 

2,933,442

 

 

$20,974,793

 

 

$(5,011,891)

 

$(8,311,633)

 

$(130,061)

 

$7,521,208

 

 

* Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025 and the 1-for-12 reverse stock split effected on July 20, 2023, on a retroactive basis.

 

See accompanying notes to the condensed consolidated financial statements.

 

 
6

Table of Contents

 

 BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$(1,884,406)

 

$(1,948,490)

 

 

 

 

 

 

 

 

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Amortization of operating lease ROU assets

 

 

46,669

 

 

 

41,666

 

Amortization of finance lease ROU assets

 

 

5,397

 

 

 

-

 

Provision for credit losses, net

 

 

76,814

 

 

 

121,030

 

Depreciation of property, plant and equipment

 

 

84,040

 

 

 

83,443

 

Dividend income

 

 

-

 

 

 

(21,752)

Fair value loss on investments in equity securities

 

 

-

 

 

 

91,243

 

Gain on disposal of investments in equity securities

 

 

-

 

 

 

(27,547)

Share-based compensation

 

 

799,998

 

 

 

-

 

Operating loss before working capital changes

 

 

(871,488)

 

 

(1,660,407)

 

 

 

 

 

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Inventories

 

 

40,477

 

 

 

381,176

 

Trade and other receivables

 

 

383,155

 

 

 

(161,860)

Other assets

 

 

(749,997)

 

 

-

 

Trade and other payables

 

 

415,090

 

 

 

(1,227,454)

Advance payment from customer

 

 

(38)

 

 

(84,615)

Operating lease liabilities

 

 

(45,105)

 

 

(26,811)

Tax recoverable

 

 

279

 

 

 

(19,473)

Net cash used in operating activities

 

 

(827,627)

 

 

(2,799,444)

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Acquisition of investments in equity securities

 

 

-

 

 

 

(9,064)

Dividend income

 

 

-

 

 

 

21,752

 

Change in fixed deposits placed with original maturities more than three months

 

 

413,584

 

 

 

(47,099)

Payment for acquisition of right-of-use assets

 

 

(21,008)

 

 

-

 

Purchase of plant and equipment

 

 

(3,103)

 

 

(35,994)

Proceeds from disposal of investments in equity securities

 

 

-

 

 

 

1,020,873

 

Net cash generated from investing activities

 

 

389,473

 

 

 

950,468

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Advances from Directors

 

 

180,798

 

 

 

32,802

 

Repayment of finance lease liabilities

 

 

(3,483)

 

 

-

 

Cash paid for fractional shares in reverse stock split

 

 

-

 

 

 

(505)

Net cash generated from financing activities

 

 

177,315

 

 

 

32,297

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

(1,679)

 

 

286,805

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

(262,518)

 

 

(1,529,874)

CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD

 

 

2,486,383

 

 

 

2,886,966

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD

 

$2,223,865

 

 

$1,357,092

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS INFORMATION:

 

 

 

 

 

 

 

 

Fixed deposits placed with financial institutions with original maturities of three-months or less

 

$1,358,061

 

 

$203,971

 

Cash and bank balances

 

 

865,804

 

 

 

1,153,121

 

Cash and cash equivalents, end of financial period

 

 

2,223,865

 

 

 

1,357,092

 

 

 

 

 

 

 

 

 

 

Supplementary cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$(11,192)

 

$(16,270)

Income tax paid

 

 

-

 

 

 

(14,669)

 

See accompanying notes to the condensed consolidated financial statements 

 

 
7

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND

 

BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 and subsequently changed its name to MRNA Scientific Sdn. Bhd. (“MRNA Scientific”) on September 19, 2023.

 

The principal office address is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5, Jalan Bangsar Utama 1, Kuala Lumpur, Malaysia, and our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia.

 

On December 31, 2020, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company, Chemrex and the Chemrex shareholders wherein the Company acquired all the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company.

 

The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity.

 

The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex was not under common control during the comparative period.

 

The corporate structure as at September 30, 2026 is depicted below:

 

 

 

BioNexus Gene Lab Corp.

 

 

 

 

a Wyoming company

 

 

 

 

 

 

 

 

100% owned 

 

 

100% owned

MRNA Scientific Sdn. Bhd. 

 

 

Chemrex Corporation Sdn. Bhd., 

 

 

 a Malaysian company

 

 

a Malaysian Company

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

 

·

Basis of presentation

 

The accompanying condensed consolidated financial statements as of and for the three- and nine-month periods ended September 30, 2026 and 2025 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) that permit reduced disclosure for interim periods. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been condensed or omitted.

 

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the period ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The Condensed Consolidated Balance Sheet information as of December 31, 2025 was derived from the Company’s audited Consolidated Financial Statements as of and for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2026. These financial statements should be read in conjunction with that report.

 

Certain prior-period amounts have been reclassified to conform to the current-period presentation. Operating lease interest of $3,100 and $9,720 for the three- and nine-month periods ended September 30, 2025, respectively, previously presented within finance costs, is now presented within general and administrative expenses. Recoveries of credit losses of $94,912 for the nine-month period ended September 30, 2025, previously presented within other income, are now presented net within provision for credit losses. Other assets of $83,333 as of December 31, 2025 have been reclassified from current assets to non-current assets. The same presentation applies to the amounts previously reported for the interim periods ended March 31 and June 30, 2026. These reclassifications had no effect on net loss, total assets, total liabilities or stockholders’ equity.

 

 
8

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

·

Going concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, for the period ended September 30, 2026, the Company recorded a net loss of $1,884,406 and net cash used in operating activities of $827,627 and as of September 30, 2026, the Company incurred an accumulated deficit of $8,311,633. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The Company's ability to continue as a going concern is dependent upon improving its operating results and obtaining additional financing. As of September 30, 2026, the Company had cash and cash equivalents and fixed deposits of $3,363,602. Its obligations over the next twelve months include unpaid license instalments of $504,330 and further license instalments of $999,996 due to Fidelion (Note 5), amounts owing to directors of $230,277, as well as its ongoing operating expenses and other working capital requirements. Although the Company has available cash and fixed deposits, these funds are also required to support its ongoing operations and meet its other financial commitments. Management plans to meet these obligations through the utilization of existing cash and fixed deposits, sales of common stock under the Company's at-the-market offering program or other financing, and continued cost control. However, the availability of additional financing is not assured, and management has concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.

 

No assurance can be given that any additional financing, if needed, will be available, or, if available, that it will be on terms satisfactory to the Company. If the Company obtains debt financing, it may be subject to restrictive covenants and repayment obligations that could adversely affect its operations. If the Company raises capital through the issuance of equity securities, existing stockholders may experience substantial dilution.

 

·

 Basis of consolidation

 

The consolidated financial statements include the accounts of BioNexus Gene Lab Corp. and its subsidiaries. Acquired businesses are included in the consolidated financial statements from the dates of acquisition. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All inter-company accounts and transactions have been eliminated in consolidation.

 

·

Use of estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to allowance for credit losses for financial assets and impairment analysis of long-lived assets. Actual results may differ from these estimates.

 

·

Cash and cash equivalents

 

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

 

The Company maintains cash balances with multiple financial institutions in Malaysia as well as in the United States. Deposits placed with each institution in Malaysia are insured by the Malaysia Deposit Insurance Corporation (Perbadanan Insurans Deposit Malaysia, or PIDM) up to RM250,000 (approximately USD 61,300) per depositor. While for deposits placed with institution in the United States, it is insured by the Federal Deposit Insurance Corporation (FDIC) up to USD250,000 per depositor, per insured bank, for each account ownership category under the FDIC’s general deposit insurance rules.

 

From time to time, the Company’s cash balances may exceed these insured limits. As of September 30, 2026, cash balances exceeding the insured limit amounted to $1,871,178. However, the Company has not experienced any losses on such accounts and believes that its exposure to credit risk is not significant. The Company actively monitors its balance with these financial institutions and considers the risk of loss to be remote.

 

·

Trade receivables

 

Trade receivables are recorded at the invoiced amount and are generally non-interest bearing. However, interest may be imposed on extended credit terms or overdue balances. The Company recognizes an allowance for credit losses in accordance with ASC 326, Financial Instruments – Credit Losses, using a current expected credit loss (CECL) model.

 

The allowance for credit losses is measured based on historical collection experience, aging of receivables, customer-specific credit risk, and current and expected future economic conditions. The Company disaggregates its trade receivables by customer type, as management has determined that risk profiles vary based on the industry and nature of the customer. For each customer type, the Company applies a historical loss rate matrix, adjusted for forward-looking information and macroeconomic trends relevant to the industries in which customers operate.

 

In addition to the collective assessment, specific allowances are established for customers with known financial difficulties or higher risk of default, based on a review of individual outstanding invoices and relevant credit information.

 

 
9

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

Trade receivables are written off against the allowance when all reasonable collection efforts have been exhausted and recovery is considered remote. The allowance for credit losses is recorded as a contra-asset account to trade receivables in the consolidated balance sheets, and changes to the allowance are recognized in the consolidated statement of operations and comprehensive income/(loss).

 

·

Inventories

 

Inventories consisting of products available for sale are stated at the lower of cost or net realizable value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated net realizable value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks, and rewards of the products purchased. Write downs are recorded in cost of revenues in the Consolidated Statement of Operations and Comprehensive Income/(Loss). 

 

·

Leases

 

The Company determines if a contract is or contains a lease at the inception of the contract or modification of the contract. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.

 

Finance and operating lease right-of-use (“ROU”) assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the implicit rate is not determinable in most of the Company’s leases, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The expected lease term includes options to extend or terminate the lease when it is reasonably certain the Company will exercise the option. Lease expense for minimum lease payments is recognized on a straight-line basis over the expected lease term. 

 

The Company’s lease arrangements have lease and non-lease components. Leases with an expected term of 12 months or less are not accounted for on the balance sheet and the related lease expense is recognized on a straight-line basis over the expected lease term.

 

·

Property, plant and equipment

 

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on a straight-line basis to write off the cost over the following expected useful lives of the assets concerned.

 

The principal annual rates used are as follows:

 

 

 

 

 

Principal

 

Categories

 

Annual Rates

 

Air conditioner

 

 

20%

Buildings

 

 

2%

Computer and software

 

 

33%

Equipment

 

 

20%

Furniture and fittings

 

10% to 20

%

Lab equipment

 

 

10%

Motor vehicle

 

10% to 20

%

Office equipment

 

 

20%

Renovation

 

10% to 20

%

Signboard

 

 

10%

Solar PV System

 

 

20%

Machinery

 

 

10%

 

Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use.

 

Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.

 

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

 

 
10

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

·

Investments in equity securities

 

The Company accounts for its investments that represent less than 20% ownership, and for which the Company does not have the ability to exercise significant influence, using ASC 321, Investments—Equity Securities. Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income. These investments are classified within “Investments in equity securities” on the consolidated balance sheets, and unrealized gains and losses are included in “Other income (expense), net” in the consolidated statement of operations and comprehensive income/(loss).

 

For equity securities without readily determinable fair values, the Company may elect the practicability exception to measure such investments at cost, less impairment, if any, plus or minus observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These securities are evaluated at each reporting period for impairment or observable price changes.

 

Realized gains and losses on sales of equity securities are determined based on the specific identification method and are also recorded in net income.

 

·

Impairment of long-lived assets

 

Long-lived assets primarily include property, plant and equipment and right-of-use assets. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets,” the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant, sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

 

·

Finance lease

 

Leases that transfer substantially all the rewards and risks of ownership to the lessee, other than legal title, are accounted for as finance leases. Substantially all of the risks or benefits of ownership are deemed to have been transferred if any one of the four criteria is met: (i) transfer of ownership to the lessee at the end of the lease term, (ii) the lease containing a bargain purchase option, (iii) the lease term exceeding 75% of the estimated economic life of the leased asset, (iv) the present value of the minimum lease payments exceeding 90% of the fair value. At the inception of a finance lease, the Company as the lessee records an asset and an obligation at an amount equal to the present value of the minimum lease payments. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company. The periodic rent payments made during the lease term are allocated between a reduction in the obligation and interest element using the effective interest method in accordance with the provisions of ASC Topic 835-30, “Imputation of Interest”.

 

·

Revenue recognition

 

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

 

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfils its obligations under each of its agreements:

 

·

identify the contract with a customer;

 

 

·

identify the performance obligations in the contract;

 

 

·

determine the transaction price;

 

 

·

allocate the transaction price to performance obligations in the contract; and

 

 

·

recognize revenue as the performance obligation is satisfied.

 

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

 

·

Shipping and handling fees

 

Shipping and handling fees, if billed to customers, are included in revenue. Shipping and handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

 

·

Comprehensive income

 

ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of cumulative foreign currency translation adjustments. This comprehensive income is not included in the computation of income tax expense or benefit.

 

 
11

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

·

Income taxes

 

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose uncertain tax positions taken in their financial statements or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

 

The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

·

Net earnings or loss per share

 

The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “Earnings per share.” Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

 

·

Share-based compensation

 

The Company accounts for share-based awards granted to employees and directors in accordance with ASC Topic 718, Compensation—Stock Compensation. Awards are measured at their grant-date fair value. The cost of awards that are fully vested when granted is recognized on the grant date, and the cost of awards with a service condition is recognized on a straight-line basis over the requisite service period.

 

·

Foreign currencies translation

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

 

The functional currency of the Company is the United States Dollar (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the subsidiaries maintain their books and records in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the subsidiaries operate.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement,” using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from the translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income.

 

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Period ended September 30, 2026 /Year-ended December 31, 2025 US$1: MYR exchange rate

 

 

4.080

 

 

 

4.061

 

 

 

 

 

 

 

 

 

 

 

 

January 1,

 

 

January 1,

 

 

 

2026 to

 

 

2025 to

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

Nine-month average US$1: MYR exchange rate

 

 

4.014

 

 

 

4.325

 

 

·

Related parties

 

Related Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

 
12

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

·

Fair value of financial instruments

 

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

·

Level 1 : Observable inputs such as quoted prices in active markets;

 

 

·

Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

 

·

Level 3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

 

The carrying value of the Company’s financial instruments: cash and bank balances, fixed deposits placed with financial institutions, trade receivable, other receivables, deposits, trade payables, other payables and accrued liabilities, advance payment from customers and amount owing to directors approximate at their fair values because of the short-term nature of these financial instruments

 

As of September 30, 2026 and December 31, 2025, respectively, the Company did not have any non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

 

·

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”).

 

Management periodically reviews new accounting standards that are issued.

 

Accounting Standards Adopted in 2025

 

Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures:

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new standard was issued to improve transparency and decision usefulness of income tax disclosures by providing information that helps investors better understand how an entity’s operations, tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The amendments in this update primarily relate to requiring greater disaggregated disclosure of information in the rate reconciliation, income taxes paid, income (loss) from continuing operations before income tax expense (benefit), and income tax expense (benefit) from continuing operations. The ASU is effective for fiscal years beginning after December 15, 2024, and early adoption is permitted. The standard can be applied prospectively or retrospectively. The Company adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in Note 5, Income Taxes.

 

Accounting Standards not yet adopted

 

Accounting Standards Update 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40):

 

Disaggregation of Income Statement Expenses:

 

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The new standard requires entities to disclose additional information about certain expenses, such as purchases of inventory, employee compensation, depreciation, intangible asset amortization, as well as selling expenses included in commonly presented expense captions on the income statement. The FASB further clarified the effective date in January 2025 with the issuance of ASU 2025-01, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Companies have the option to apply this guidance either on a retrospective or prospective basis, and early adoption is permitted.

 

The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.

 

 
13

Table of Contents

 

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

The Company does not expect that any other recently issued accounting pronouncements will have a significant effect on its consolidated financial statements.

 

NOTE 3 – TRADE RECEIVABLES

 

Trade receivables included amounts due from related parties of $nil and $31,420 as of September 30, 2026 and December 31, 2025, respectively. Trade receivables are initially recognized at the invoiced amount and subsequently measured at amortized cost, net of an allowance for credit losses. An allowance for credit losses is recognised based on the Company’s estimate of expected credit losses. Trade receivables are written off when they are determined to be uncollectible and all reasonable collection efforts have been exhausted.

 

As of September 30, 2026, the Company performed an assessment of its outstanding trade receivables in accordance with the current expected credit loss (CECL) model under ASC 326. In estimating the allowance for credit losses, the Company considered historical collection trends, the aging of outstanding balances, customer credit profiles, and current and reasonable and supportable forecasts of future economic conditions..

 

The Company’s standard credit terms range from 30 to 90 days. Certain receivables are interest-bearing. Specifically, one customer was charged with interest at 6% per annum from May 2021 to June 2023. From July 2023 onwards, the Company increased its interest rate to 8.4%.

 

 

 

As of

 

 

 

September 30,

2026

 

 

December 31,

2025

 

 

 

 

 

 

 

 

Trade receivables

 

 

811,446

 

 

 

1,209,880

 

Allowances for expected credit losses

 

 

(773,304)

 

 

(703,995 )

Total trade receivables, net

 

$38,142

 

 

$505,885

 

 

Movement for trade receivables allowance for impairment accounts:

 

 

 

As of

 

 

 

September 30,

2026

 

 

December 31,

2025

 

At January 1, 2026 and January 1, 2025

 

 

703,995

 

 

 

517,877

 

Charge for the period/year

 

 

 

 

 

 

 

 

Allowances for expected credit losses

 

 

270,661

 

 

 

225,756

 

Recovered for expected credit losses

 

 

(193,847)

 

 

(97,203 )

Foreign translation differences

 

 

(7,505)

 

 

57,565

 

 

 

$773,304

 

 

$703,995

 

 

 
14

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

NOTE 4 – INCOME TAXES

 

Loss before income taxes for the nine-month periods ended September 30, 2026 and 2025 is summarized as follows:

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

Loss before income taxes:

 

 

 

 

 

 

Local

 

$(1,424,809 )

 

$(638,342 )

Foreign, representing Malaysia

 

 

(459,597 )

 

 

(1,310,148 )

 

 

$(1,884,406)

 

$(1,948,490)

 

Provision for income taxes for the nine-month periods ended September 30, 2026 and 2025 is summarized as follows: 

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

Current expense/(benefit):

 

 

 

 

 

 

Federal

 

$-

 

 

$-

 

State

 

 

-

 

 

 

-

 

Foreign

 

 

-

 

 

 

-

 

Total current expense

 

 

-

 

 

 

-

 

Deferred expense/(benefit):

 

 

 

 

 

 

 

 

Federal

 

 

-

 

 

 

-

 

State

 

 

-

 

 

 

-

 

Foreign

 

 

-

 

 

 

-

 

Total deferred expense/(benefit)

 

 

-

 

 

 

-

 

Total income tax expense

 

$-

 

 

$-

 

 

The income taxes paid/(net of refunds) by jurisdiction for nine-month periods ended September 30, 2026 and 2025, as reported in the Consolidated Statements of Cash Flows, are as follows:

 

 

 

Nine-month periods ended

 

 

 

September 30, 2026

 

 

September 30,

2025

 

U.S. federal

 

$-

 

 

$-

 

Foreign, Malaysia

 

$-

 

 

$(14,669 )

Total income taxes paid, net

 

$-

 

 

$(14,669 )

 

The reconciliation of the federal statutory income tax amount and rate to the Company’s effective tax rate for nine-month periods ended September 30, 2026 and 2025 is as follows:

 

 

 

Nine-month periods ended

 

 

 

September 30, 2026

 

 

September 30, 2025

 

 

 

$

 

 

 %

 

 

$

 

 

 %

 

Loss before tax

 

 

(1,884,406 )

 

 

-

 

 

 

(1,948,490 )

 

 

-

 

Federal statutory tax rate

 

 

(395,725 )

 

 

21.00%

 

 

(409,183 )

 

 

21.00%

State and local income taxes, net of federal income tax effect

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Foreign tax effects:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Malaysia

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign rate difference

 

 

(13,788 )

 

 

0.73%

 

 

(39,304 )

 

 

2.02%

Non-taxable or non-deductible items

 

 

26,353

 

 

 

(1.40 )%

 

 

71,608

 

 

 

(3.68 )%

Prior year tax adjustment

 

 

-

 

 

 

0.00%

 

 

-

 

 

 

0.00%

Changes in valuation allowances

 

 

383,160

 

 

 

(20.33 )%

 

 

376,878

 

 

 

(19.34 )%

Income tax expense and effective tax rate

 

 

-

 

 

 

0.00%

 

 

-

 

 

 

0.00%

 

 
15

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

The significant components of deferred taxes of the Company are as follows:

 

 

 

As of

 

 

 

September 30,

2026

 

 

December 31,

2025

 

Deferred tax assets

 

 

 

 

 

 

Property, plant and equipment

 

$(230,122)

 

 

(227,990)

Capital allowances

 

 

399,202

 

 

 

343,634

 

Net operating loss (NOL) carryforwards:

 

 

 

 

 

 

 

 

– United States of America

 

 

10,362,931

 

 

 

8,938,122

 

– Malaysia

 

 

2,673,932

 

 

 

2,377,575

 

Gross deferred tax assets

 

 

13,205,943

 

 

 

11,431,341

 

Less: Valuation allowance

 

 

(13,205,943)

 

 

(11,431,341)

Deferred tax assets, net of valuation allowance

 

 

-

 

 

 

-

 

 

The table below summarizes changes in the valuation allowance for deferred tax assets for the nine-month period ended September 30, 2026 and 2025 presented:

 

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

Valuation allowance

 

 

 

 

 

 

Balance, beginning of period

 

$11,431,341

 

 

 

9,485,211

 

Increases in (reversal of) valuation allowance during the period

 

 

1,774,602

 

 

 

 1,650,119

 

Balance, end of period

 

$13,205,943

 

 

 

11,135,330

 

 

The Company believes that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company established a valuation allowance of $13,205,943 to offset deferred tax assets of $13,205,943, including deferred tax assets related to net operating loss (NOL) carryforwards of $13,036,863, as of September 30, 2026.

 

For the nine-month period ended September 30, 2026, the valuation allowance increased by $1,774,602, primarily due to increases in NOL carryforwards of $1,424,809 in the United States and $296,357 in Malaysia.

 

United States of America

 

The Company is registered in the State of Wyoming and is subject to United States of America tax law.

 

For the nine-month periods ended September 30, 2026 and 2025, the operations in the United States of America incurred a net operating loss (NOL) of $1,424,809 and $638,342 respectively.

 

As of September 30, 2026, the cumulative U.S. federal net operating losses (NOLs) were $10,362,931. Federal NOLs arising in tax years beginning after December 31, 2017 may be carried forward indefinitely but may offset only 80% of taxable income in any year.

 

Malaysia

 

The Company’s subsidiaries operating in Malaysia are subject to the Malaysia Corporate Tax Laws at a standard income tax rate of 24% on their assessable income for the tax year.

 

For the nine-month periods ended September 30, 2026 and 2025, the subsidiaries in Malaysia incurred an aggregate net operating loss (NOL) of $296,357 and $958,944, respectively.

 

As of September 30, 2026, the operations in Malaysia had incurred the aggregate amount of cumulative net operating losses (NOLs) of $2,673,932 which can be carried forward for up to ten consecutive years of assessment to offset future taxable income. The NOL carryforwards begin to expire in 2033, if unutilized.

 

 
16

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 5 – OTHER ASSETS

 

On November 28, 2025, the Company entered into an Exclusive Intellectual Property License Agreement (the “License Agreement”) with Fidelion Diagnostics Pte. Ltd. (“Fidelion”), pursuant to which the Company received an exclusive, irrevocable license to use, develop, manufacture, market, distribute, and sell products utilizing the VitaGuard™ minimal residual disease (“MRD”) liquid biopsy platform in the member states of the Association of Southeast Asian Nations (“ASEAN”). The License Agreement was entered into together with the Share Subscription and Shareholders’ Agreement between the Company and Fidelion, among others, whereby Fidelion issued to the Company 180 Ordinary Shares (approximately 15% of Fidelion’s share capital) and the Company issued 392,329 shares of its restricted common stock to Fidelion (approximately 16.6% of the Company’s issued and outstanding common stock). 

 

In consideration for the license, the Company agreed to pay Fidelion a total license fee of $2,000,000 in 24 equal monthly instalments of $83,333, commencing in December 2025. Delivery and verification of the licensed technology package remain in progress (see Part II, Item 1A). The Company records each instalment as it falls due as a deposit toward the license within Other Assets, classified as a non-current asset, and has not recognized the license rights as a separate intangible asset as of September 30, 2026. As of September 30, 2026, instalments of $833,330 had fallen due, of which $504,330 remained unpaid and is included in other payables (Note 11). The remaining instalments of $1,166,670, of which $999,996 fall due within the next twelve months, are a commitment of the Company and are not recognized in the condensed consolidated balance sheet.

 

NOTE 6 – OPERATING LEASE RIGHT OF USE ASSETS AND LEASE LIABILITIES

 

The Company has operating lease arrangements for office space, lab, and motor vehicles in Malaysia with a term between two and five years. The Company accounts for the lease and non-lease components of its leases as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.

 

Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

 

The present value of the lease payments is discounted at 6.65% per annum. This rate is reference from base rate of Malayan Banking Berhad, the largest bank in Malaysia.

 

As of September 30, 2026 and December 31, 2025, operating lease right-of-use assets are as follows:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Balance as of beginning of the period/year

 

$177,737

 

 

$215,243

 

Less: amortization

 

 

(46,669)

 

 

(56,434 )

Foreign translation differences

 

 

(51)

 

 

18,928

 

Balance as of end of the period/year

 

$131,017

 

 

$177,737

 

 

As of September 30, 2026 and December 31, 2025, operating lease liabilities are as follows:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Balance as of beginning of the period/year

 

$176,046

 

 

$210,557

 

Less: gross repayment

 

 

(52,637)

 

 

(65,817 )

Add: imputed interest

 

 

7,611

 

 

 

12,677

 

Foreign translation differences

 

 

(79)

 

 

18,629

 

Balance as of end of the period/year

 

 

130,941

 

 

 

176,046

 

Less: operating lease liability current portion

 

 

(55,506)

 

 

(59,147 )

Operating lease liability non-current portion

 

$75,435

 

 

$116,899

 

 

 
17

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

As of September 30, 2026 and December 31, 2025, the maturities of the operating lease obligation are as follows:

 

 

 

As of

 

 

 

September 30,

2026

 

 

December 31,

2025

 

 

 

 

 

 

 

 

Years ending September 30 and December 31:

 

 

 

 

 

 

2026

 

 

-

 

 

 

68,671

 

2027

 

 

62,159

 

 

 

61,058

 

2028

 

 

56,289

 

 

 

49,776

 

2029

 

 

22,552

 

 

 

14,159

 

Total undiscounted cash flows

 

 

141,000

 

 

 

193,664

 

Less: Interest imputed in operating lease liabilities

 

 

(10,059)

 

 

(17,618 )

Present value of operating lease liabilities

 

$130,941

 

 

$176,046

 

 

The amortization of the operating lease right of use asset for the nine-month periods ended September 30, 2026 and 2025 were $46,669 and $41,666 respectively.

 

 

 

As of

 

 

 

September 30,

2026

 

 

December 31,

2025

 

Supplemental Cash Flow Disclosures:

 

 

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

Lease payment – operating leases

 

$(52,637)

 

$(65,817)

 

 

 

 

 

 

 

 

 

Other information:

 

 

 

 

 

 

 

 

Weighted average remaining lease term for operating lease (years)

 

 

2.67

 

 

 

3.42

 

Weighted average discount rate for operating lease

 

 

6.65%

 

 

6.65%

 

Lease expenses for the nine-month periods ended September 30, 2026 and 2025 were $54,280 and $51,386, respectively.

 

 
18

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 7 – FINANCE LEASE RIGHT OF USE ASSET AND LEASE LIABILITY

 

The Company purchased motor vehicles under finance lease agreements with the effective interest rate of 5.12% of per annum, with principal and interest payable monthly. The obligations under the finance lease are as follows:

 

As of September 30, 2026 and December 31, 2025, finance lease right-of-use assets are as follows:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Addition of right of use assets

 

 

75,383

 

 

 

-

 

Less: amortization

 

 

(5,397)

 

 

-

 

Foreign translation differences

 

 

(562)

 

 

-

 

Balance as of September 30, 2026

 

$69,424

 

 

$-

 

 

The amortization of right of use assets is on a straight-line basis over 84 months (approximately $897 per month), commence from April 1, 2026 onwards.

 

The first repayment of the finance lease liabilities will also fall due from April 1, 2026 onwards.

 

As of September 30, 2026 and December 31, 2025, finance lease liabilities are as follows: 

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Balance as of beginning of the period/year

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Addition of finance lease liabilities

 

 

54,375

 

 

 

-

 

Less: gross repayment

 

 

(4,667)

 

 

-

 

Add: imputed interest

 

 

1,574

 

 

 

-

 

Foreign translation differences

 

 

(390)

 

 

-

 

Balance as of end of the period/year

 

$50,892

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Less: current portion of finance lease liabilities

 

 

(6,862)

 

 

-

 

Finance lease liabilities, non-current

 

$44,030

 

 

 

-

 

 

 
19

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

As of September 30, 2026 and December 31, 2025, the maturities of the finance lease obligation are as follows:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Years ending September 30 and December 31:

 

 

 

 

 

 

2027

 

 

9,183

 

 

 

-

 

2028

 

 

9,183

 

 

 

-

 

2029

 

 

9,183

 

 

 

-

 

2030

 

 

9,183

 

 

 

-

 

2031

 

 

9,183

 

 

 

-

 

Thereafter

 

 

13,765

 

 

 

-

 

Total undiscounted lease payments

 

 

59,680

 

 

 

-

 

Less: Imputed Interest on finance lease liabilities

 

 

(8,788)

 

 

-

 

Present value of finance lease liabilities

 

$50,892

 

 

$-

 

 

The amortization of the finance lease right of use asset for the nine-month period ended September 30, 2026 and 2025 were $5,397 and $nil respectively.

 

Supplemental Cash Flow Disclosures:

 

 

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

Lease payment – finance leases

 

$

(4,667

)

 

$-

 

Payment for acquisition of right-of-use assets

 

 

 (21,008

) 

 

 

 -

 

Right-of-use assets obtained in exchange for new finance lease liabilities (non-cash)

 

 

 54,375

 

 

 

 -

 

 

 

 

 

 

 

 

 

 

Other information:

 

 

 

 

 

 

 

 

Weighted average remaining lease term for finance lease (years)

 

 

6.50

 

 

 

-

 

Weighted average discount rate for finance lease

 

 

5.12%

 

 

-

 

 

Lease expenses for the nine-month periods ended September 30, 2026 and 2025 were $6,971 and $nil respectively.

 

During the nine-month period ended September 30, 2026, the Company obtained finance lease right-of-use assets of $75,383 in exchange for finance lease liabilities of $54,375 and a down payment of $21,008.

 

 
20

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 8 – PROPERTY, PLANT AND EQUIPMENT

 

 Property, plant and equipment consisted of the following:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Air conditioner

 

$1,124

 

 

$1,124

 

Computer and software

 

 

7,426

 

 

 

7,262

 

Equipment

 

 

65,360

 

 

 

65,360

 

Furniture and fittings

 

 

98,883

 

 

 

98,883

 

Lab equipment

 

 

320,102

 

 

 

320,102

 

Land and buildings

 

 

1,506,969

 

 

 

1,506,969

 

Motor vehicle

 

 

161,148

 

 

 

161,148

 

Office equipment

 

 

44,047

 

 

 

41,108

 

Renovation

 

 

111,519

 

 

 

111,519

 

Signboard

 

 

806

 

 

 

806

 

Solar PV System

 

 

16,935

 

 

 

16,935

 

Machinery

 

 

211,898

 

 

 

211,898

 

 

 

 

2,546,217

 

 

 

2,543,114

 

(Less): Accumulated depreciation

 

 

(952,889)

 

 

(868,849 )

(Less): Accumulated impairment

 

 

(40,173)

 

 

(40,173 )

Add: Foreign translation differences

 

 

(41,225)

 

 

(35,323 )

Property, plant and equipment, net

 

$1,511,930

 

 

$1,598,769

 

 

During the nine-month periods ended September 30, 2026 and 2025, the Company recorded depreciation of $84,040 and $83,443, respectively.

 

 
21

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 9 – INVESTMENTS IN EQUITY SECURITIES

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

As of beginning of the period/year

 

 

2,027,540

 

 

 

1,265,166

 

Addition during the year

 

 

-

 

 

 

1,790,333

 

Disposal during the year

 

 

-

 

 

 

(1,004,428 )

Fair value (loss)/gain

 

 

-

 

 

 

(93,965 )

Foreign exchange translation

 

 

(1,117)

 

 

70,434

 

As of end of the period/year

 

 

2,026,423

 

 

 

2,027,540

 

 

For the nine-month periods ended September 30, 2026 and 2025, the net fair value gain/(loss) on the investments in equity securities was $nil and $(91,243), respectively, recorded in administrative expenses and other income of the Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss).

 

 The investments in equity securities consist of the following shares:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Investment in equity securities without readily determined fair value:

 

 

 

 

 

 

Malaysia

 

 

245,249

 

 

 

246,366

 

Singapore

 

 

1,781,174

 

 

 

1,781,174

 

 

 

$2,026,423

 

 

$2,027,540

 

 

Equity Securities Without Readily Determinable Fair Values

 

The Company’s investments in equity securities without readily determinable fair values consist of investments in privately held companies and totaled $2,026,423 and $2,027,540 as of September 30, 2026 and December 31, 2025, respectively.

 

These investments are accounted for in accordance with ASC 321, Investments—Equity Securities, using the measurement alternative, under which such securities are measured at cost, less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.

 

The Company evaluates these investments for impairment on a quarterly basis by performing a qualitative assessment to determine whether the fair value of an investment is less than its carrying amount. If an impairment is identified, the investment is written down to its fair value, with the loss recognized in earnings. In addition, the carrying value of these investments is adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

 

Because these investments are in privately held companies and lack observable market prices, the determination of fair value for impairment assessments requires significant judgment. When such investments are remeasured due to impairment or observable price changes, the resulting fair value measurements are classified within Level 3 of the fair value hierarchy.

 

For fiscal year 2025, the Company issued 392,329 shares of common stock at a value of $1,781,174 to Fidelion Diagnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This transaction formed part of the conditions under the previously disclosed Share Subscription and Shareholders’ Agreement entered into with Fidelion and Tongshu Biotechnology (Hong Kong) Co., Limited.

 

 
22

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 10 – TRADE PAYABLES

 

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

 

NOTE 11 – OTHER PAYABLES AND ACCRUED LIABILITIES

 

As of September 30, 2026, other payables comprised mainly amounts owing to service providers and unpaid license instalments of $504,330 due to Fidelion under the License Agreement (Note 5). Other than the Fidelion instalments, the amounts have short payment terms.

 

 

 

As of

September 30, 

2026

 

 

As of

December 31, 

2025

 

 

 

 

 

 

 

 

Other payables and accrued liabilities (including $504,330 and $83,333 of other payables to related party as of September 30, 2026 and December 31, 2025 respectively)

 

 

723,435

 

 

 

275,574

 

Accrued liabilities

 

 

83,084

 

 

 

126,036

 

 

 

$806,519

 

 

$401,611

 

 

 
23

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 12 – REVENUE

 

The following table shows disaggregated net revenue from contracts with customers by product or service line and geographic area for the three- and nine-month periods ended September 30, 2026 and 2025:

 

 

 

Three-month periods ended

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue by product or service line:

 

 

 

 

 

 

 

 

 

 

 

 

Trading of industrial chemicals

 

 

47,917

 

 

 

2,539,055

 

 

 

144,954

 

 

 

6,929,849

 

Screening services and related sales

 

 

-

 

 

 

4,768

 

 

 

1,961

 

 

 

11,302

 

Net revenue

 

$47,917

 

 

$2,543,823

 

 

$146,915

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue by geographic area:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bangladesh

 

 

-

 

 

 

78,184

 

 

 

-

 

 

 

107,036

 

Malaysia

 

 

45,936

 

 

 

1,776,300

 

 

 

132,495

 

 

 

5,354,391

 

Maldives

 

 

-

 

 

 

356,684

 

 

 

-

 

 

 

677,333

 

Singapore

 

 

-

 

 

 

108,247

 

 

 

-

 

 

 

240,093

 

Sri Lanka

 

 

-

 

 

 

193,053

 

 

 

-

 

 

 

448,523

 

Indonesia

 

 

-

 

 

 

31,355

 

 

 

-

 

 

 

113,775

 

South Africa

 

 

1,981

 

 

 

-

 

 

 

14,420

 

 

 

-

 

Net revenue

 

$47,917

 

 

$2,543,823

 

 

$146,915

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Timing of recognition:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At a point in time

 

$47,917

 

 

$2,543,823

 

 

$146,915

 

 

$6,941,151

 

 

Revenue is derived from the sale of industrial chemicals and the provision of genomic screening services. Revenue from the sale of goods is recognized at a point in time when control of the goods is transferred to the customer. Credit terms are generally from 30 to 90 days. The Company allows returns only for exchanges with new goods. No warranties are given on the sale of goods.

 

Revenue from services is recognized at a point in time when the final report is delivered to the customer. Credit terms for these services are generally from 30 days to 60 days. No warranties are given on the services rendered.

 

In applying ASC 606, the Company does not exercise significant judgment in determining whether revenue from the sale of goods and services should be recognized at a point in time. The criteria for recognizing revenue at a point in time, such as the transfer of control of goods or completion of services, are clear and are based on established contract terms. Therefore, no significant judgment is required in determining the timing of revenue recognition.

 

NOTE 13 – RELATED PARTY TRANSACTIONS

 

The following table provides details of the total revenue earned and expenses incurred from all related party transactions:

 

 

 

Three-month periods ended

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Entities in which former directors of a subsidiary have substantial financial interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of goods

 

$-

 

 

$25,649

 

 

$-

 

 

$57,632

 

Purchases

 

 

-

 

 

 

(7,233)

 

 

-

 

 

 

(9,404)

Rental of factory

 

 

-

 

 

 

(1,065)

 

 

-

 

 

 

(3,156)

 

The balances related to the above transactions with related parties are as disclosed in the Condensed Consolidated Balance Sheets which are interest-free, unsecured and subject to normal credit terms.

 

 
24

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

The related parties consist of (i) companies in which former directors of a subsidiary have substantial financial interests; (ii) Fidelion, in which the Company’s Chief Executive Officer has a shareholding and serves as chief executive officer-designate, and which held 392,329 shares, or approximately 13.4%, of the Company’s common stock as of September 30, 2026; and (iii) the Company’s directors.

 

Under the License Agreement with Fidelion (Note 5), license instalments of $249,999 and $749,997 fell due during the three- and nine-month periods ended September 30, 2026, respectively, and were recorded within Other Assets. Unpaid instalments of $504,330 and $83,333 were included in other payables as of September 30, 2026 and December 31, 2025, respectively.

 

During the nine-month period ended September 30, 2026, directors advanced $180,798 to the Company. Amounts owing to directors were $230,277 and $49,479 as of September 30, 2026 and December 31, 2025, respectively, and are unsecured and interest-free.

 

NOTE 14 – CONCENTRATION OF RISKS

 

Customers and suppliers are identified by letter separately for each period presented.

 

a) Major customers

 

For the three-month periods ended September 30, 2026, and 2025, respectively, the customers who accounted for 10% or more of the Company’s revenues and its accounts received balance at period-end are presented as follows:

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

Revenues

 

 

Percentage of revenues

 

 

Accounts receivable trade

 

Customer A

 

$9,168

 

 

$-

 

 

 

19.13%

 

 

-

 

 

$9,154

 

 

$-

 

Customer B

 

$6,590

 

 

$-

 

 

 

13.75%

 

 

-

 

 

$9,421

 

 

$-

 

Customer C

 

$-

 

 

$287,262

 

 

 

-

 

 

 

11.29%

 

$-

 

 

$240,594

 

 

 

$15,758

 

 

$287,262

 

 

 

32.89%

 

 

11.29%

 

$18,575

 

 

$240,594

 

 

For the nine-month periods ended September 30, 2026, and 2025, respectively, the customers who accounted for 10% or more of the Company’s revenues and its accounts received balance at period-end are presented as follows:

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

Revenues

 

 

Percentage of revenues

 

 

Accounts receivable trade

 

Customer A

 

$29,371

 

 

$-

 

 

 

19.99%

 

 

-

 

 

$-

 

 

$-

 

 

 

$29,371

 

 

$-

 

 

 

19.99%

 

 

-

 

 

$-

 

 

$-

 

 

b) Major suppliers

 

For the three-month periods ended September 30, 2026, and 2025, respectively, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at period ended are presented as follows:

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

Purchase

 

 

Percentage of purchases

 

 

Accounts payable trade

 

Vendor A

 

$9,397

 

 

$-

 

 

 

21.64%

 

 

-

 

 

$8,582

 

 

$-

 

Vendor B

 

$4,709

 

 

$-

 

 

 

10.84%

 

 

-

 

 

$2,158

 

 

$-

 

Vendor C

 

$-

 

 

$407,648

 

 

 

-

 

 

 

18.82%

 

$-

 

 

$-

 

Vendor D

 

$-

 

 

$380,771

 

 

 

-

 

 

 

17.58%

 

$-

 

 

$94,145

 

Vendor E

 

$-

 

 

$230,019

 

 

 

-

 

 

 

10.62%

 

$-

 

 

$-

 

 

 

$14,106

 

 

$1,018,438

 

 

 

32.48%

 

 

47.02%

 

$10,740

 

 

$94,145

 

 

For the nine-month periods ended September 30, 2026, and 2025, respectively, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at period ended are presented as follows:

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

Purchase

 

 

Percentage of purchases

 

 

Accounts payable trade

 

Vendor A

 

$19,932

 

 

$-

 

 

 

15.30%

 

 

-

 

 

$-

 

 

$-

 

Vendor B

 

$17,003

 

 

$-

 

 

 

13.06%

 

 

-

 

 

$8,582

 

 

$-

 

Vendor C

 

$-

 

 

$1,494,227

 

 

 

-

 

 

 

25.53%

 

$-

 

 

$-

 

Vendor D

 

$-

 

 

$939,970

 

 

 

-

 

 

 

16.06%

 

$-

 

 

$94,145

 

 

 

$36,935

 

 

$2,434,197

 

 

 

28.36%

 

 

41.59%

 

$8,582

 

 

$94,145

 

 

 
25

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 15 – STOCKHOLDERS’ EQUITY

 

As at September 30, 2026 and December 31, 2025, the Company’s issued and outstanding common stock was 2,933,442 and 2,417,314 shares, respectively.

 

Reverse Stock Split

 

On March 19, 2025, the Company held a Special Meeting of Shareholders which, among other items, approved of an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding shares of common stock, with a ratio ranging from one-for-five (1:5) to one-for-ten (1:10), with the exact ratio to be set at the discretion of the Board of Directors. Thereafter, on that same date, the Board of Directors set the reverse stock split ratio at 1 for 10.

 

On April 1, 2025, the Company filed its Articles of Amendment with the Wyoming Secretary of State to effect a one for ten (1 for 10) reverse stock split of its issued and outstanding common stock, which became market effective on April 7, 2025. Immediately prior to the reverse stock split, the Company had 17,967,663 shares of common stock issued and outstanding and immediately after the reverse stock split, the Company had 1,796,597 shares of common stock issued and outstanding. No fractional shares were issued in connection with the reverse stock split. Instead, shareholders who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof based on the daily Volume Weighted Average Price (VWAP) of our common stock, calculated for ten (10) trading days immediately preceding the effective date of the Reverse Stock Split, multiplied by the fractional share.

 

Shelf Filing

 

On November 7, 2025, the Company filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) to register up to $100 million of securities that may be offered from time to time. The Company concurrently entered into an Equity Distribution Agreement (the “Agreement”) with Maxim Group LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, shares of its common stock, no par value (the “Common Stock”), having an aggregate offering price of up to $20,000,000 through the Agent, acting as the Company’s exclusive sales agent (the “ATM Program”).

 

Sales, if any, will be made in transactions deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, which may be made directly on The Nasdaq Capital Market or otherwise at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices, as permitted by the Agreement. The Company is not obligated to sell any shares under the ATM Program, and the Agent is not required to purchase any shares. The Form S-3 became effective on November 27, 2025. As of the date of this report, the Company had sold 53,478 shares under the ATM Program for proceeds of $267,311, all of which were sold in 2025.

 

Additional Share Issuances

 

In November 2025, the Company issued 175,000 shares of common stock to ARC Group International Ltd. (“ARC”) as consideration for ARC’s commitment under the purchase agreement to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share, over a 36-month period. As of the date of this report, ARC has not purchased any shares under the purchase agreement.

 

In November 2025, the Company issued 392,329 shares of common stock to Fidelion Diagnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This issuance was a result of the Share Subscription and Shareholders’ Agreement with Fidelion and Tongshu Biotechnology (Hong Kong) Co., Limited, among others, which closed on November 28, 2025.

 

On August 13, 2026, the Company issued an aggregate of 516,128 shares of its common stock, no par value per share, under the Company’s shareholder-approved 2025 Equity Incentive Plan. Each award was a fully vested Other Stock-Based Award under Section 5 of the plan, issued on a bonus basis as compensation for completed services and for no cash consideration. The awards were measured at a grant-date fair value of $1.55 per share, based on the Nasdaq closing price on August 12, 2026, the last closing price before the awards were granted, for an aggregate of $799,998, which was recognized as share-based compensation expense in the three-month period ended September 30, 2026.

 

 
26

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 16 – SEGMENT INFORMATION

 

The Company determines its reportable segments based on its internal organization structure and internal management reporting used to assess and allocate resources. This information is regularly reviewed by the Company’s Chief Executive Officer who is identified as the Chief Operating Decision Maker (“CODM”). The Company consists of three operating units, BioNexus Gene Lab Corp., MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. which are determined as three reportable segments, as described below. These reportable segments offer different products and services, and are managed separately because they require different technology and marketing strategies. The following describes the operations in each of the Company’s reportable segments:

 

·

Trading of industrial chemicals

-

Includes trading of industrial chemicals

·

Provision for genomic screening services

-

includes in commercializing proprietary blood-based diagnostic test for early disease detection

·

Investment holding

-

Investment holding

 

The CODM evaluates the performance of each reportable segment based on operating income and key segment-specific metrics. There are no inter-segment revenue transactions between reportable segments. Except for investment holding activities and the revenue to the overseas customers as disclosed in Note 12, the Company’s revenue and principal operations are substantially confined within Malaysia.

 

The CODM evaluates segment performance primarily on operating income and reviews the following expense categories by segment: cost of revenue, selling and distribution, and administrative expenses. A reconciliation of total reportable segment amounts to the Company’s consolidated amounts is provided below, with corporate and unallocated items presented as reconciling adjustments.

 

Pursuant to ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, the financial information concerning the Company’s reportable segments is shown as below:

 

 
27

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

Nine-month periods:

 

By Business Unit

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

Nine-month periods ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$1,961

 

 

$144,954

 

 

$-

 

 

$146,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(1,250)

 

 

(128,985)

 

 

-

 

 

 

(130,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

711

 

 

 

15,969

 

 

 

-

 

 

 

16,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

38,273

 

 

 

16,630

 

 

 

-

 

 

 

54,903

 

Gain from foreign exchange

 

 

8,227

 

 

 

1,790

 

 

 

48

 

 

 

10,065

 

Others

 

 

-

 

 

 

22,779

 

 

 

-

 

 

 

22,779

 

TOTAL OTHER INCOME

 

 

46,500

 

 

 

41,199

 

 

 

48

 

 

 

87,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(98,154)

 

 

(2,790)

 

 

(22,818)

 

 

(123,762)

Research and development

 

 

(41,736)

 

 

-

 

 

 

-

 

 

 

(41,736)

General and administrative

 

 

(180,877)

 

 

(162,031)

 

 

(600,034)

 

 

(942,942)

Provision for credit losses, net

 

 

-

 

 

 

(76,814)

 

 

-

 

 

 

(76,814)

Share-based compensation

 

 

-

 

 

 

-

 

 

 

(799,998)

 

 

(799,998)

TOTAL OPERATING EXPENSES

 

 

(320,767)

 

 

(241,635)

 

 

(1,422,850)

 

 

(1,985,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(273,556)

 

 

(184,467)

 

 

(1,422,802)

 

 

(1,880,825)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

-

 

 

 

(1,574)

 

 

(2,007)

 

 

(3,581)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(273,556)

 

 

(186,041)

 

 

(1,424,809)

 

 

(1,884,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(273,556)

 

$(186,041)

 

$(1,424,809)

 

$(1,884,406)

 

 

 
28

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

 

 

Provision for

 

 

 

 

 

 

 

 

 

 

 

 

genomic

 

 

Trading of

 

 

 

 

 

 

 

 

 

screening

 

 

industrial

 

 

Investment

 

 

 

 

 

 

services

 

 

chemicals

 

 

holding

 

 

Total

 

 

 

Nine months period ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$11,302

 

 

$6,929,849

 

 

$-

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(4,995)

 

 

(5,846,956)

 

 

-

 

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

6,307

 

 

 

1,082,893

 

 

 

-

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

-

 

 

 

21,752

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

63,646

 

 

 

10,468

 

 

 

-

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

-

 

 

 

28,256

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

-

 

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Others

 

 

10,919

 

 

 

136,312

 

 

 

-

 

 

 

147,231

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL OTHER INCOME

 

 

74,565

 

 

 

239,164

 

 

 

-

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(86,275)

 

 

(1,577,214)

 

 

(37,202)

 

 

(1,700,691)

Research and development

 

 

(39,572)

 

 

-

 

 

 

-

 

 

 

(39,572)

General and administrative

 

 

(270,725)

 

 

(492,464)

 

 

(600,888)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

-

 

 

 

(119,499)

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

-

 

 

 

(121,030)

 

 

-

 

 

 

(121,030)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL OPERATING EXPENSES

 

 

(396,572)

 

 

(2,310,207)

 

 

(638,090)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(315,700)

 

 

(988,150)

 

 

(638,090)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(32)

 

 

(6,266)

 

 

(252)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(315,732)

 

 

(994,416)

 

 

(638,342)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(315,732)

 

$(994,416)

 

$(638,342)

 

$(1,948,490)

 

 
29

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

By Country

 

Malaysia

 

 

United States

 

 

Total

 

 

 

Nine-month period ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$146,915

 

 

$-

 

 

$146,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(130,235)

 

 

-

 

 

 

(130,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

16,680

 

 

 

-

 

 

 

16,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

54,903

 

 

 

-

 

 

 

54,903

 

Gain from foreign exchange

 

 

10,017

 

 

 

48

 

 

 

10,065

 

Others

 

 

22,779

 

 

 

-

 

 

 

22,779

 

TOTAL OTHER INCOME

 

 

87,699

 

 

 

48

 

 

 

87,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(100,944)

 

 

(22,818)

 

 

(123,762)

Research and development

 

 

(41,736)

 

 

-

 

 

 

(41,736)

General and administrative

 

 

(342,908)

 

 

(600,034)

 

 

(942,942)

Provision for credit losses, net

 

 

(76,814)

 

 

-

 

 

 

(76,814)

Share-based compensation

 

 

-

 

 

 

(799,998)

 

 

(799,998)

TOTAL OPERATING EXPENSES

 

 

(562,402)

 

 

(1,422,850)

 

 

(1,985,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(458,023)

 

 

(1,422,802)

 

 

(1,880,825)

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,574)

 

 

(2,007)

 

 

(3,581)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(459,597)

 

 

(1,424,809)

 

 

(1,884,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(459,597)

 

$(1,424,809)

 

$(1,884,406)

 

 

By Country

 

Malaysia

 

 

United States

 

 

Total

 

 

 

Nine-month period ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$6,941,151

 

 

$-

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(5,851,951)

 

 

-

 

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

1,089,200

 

 

 

-

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

21,752

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

74,114

 

 

 

-

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

28,256

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Others

 

 

147,231

 

 

 

 

 

 

 147,231

 

TOTAL OTHER INCOME

 

 

313,729

 

 

 

-

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(1,663,489)

 

 

(37,202)

 

 

(1,700,691)

Research and development

 

 

(39,572)

 

 

-

 

 

 

(39,572)

General and administrative

 

 

(763,189)

 

 

(600,888)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

(119,499)

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

(121,030)

 

 

-

 

 

 

(121,030)

TOTAL OPERATING EXPENSES

 

 

(2,706,779)

 

 

(638,090)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,303,850)

 

 

(638,090)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(6,298)

 

 

(252)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(1,310,148)

 

 

(638,342)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(1,310,148)

 

$(638,342)

 

$(1,948,490)

 

 

 
30

Table of Contents

 

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

 

 

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

As of September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

 

$1,643,808

 

 

$4,250,922

 

 

$2,865,971

 

 

$8,760,701

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Included in the measure of segment assets are:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Addition to non-current assets other than financial instruments and deferred tax assets

 

 

163

 

 

 

78,323

 

 

 

-

 

 

 

78,486

 

 

 

 

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

As of December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

 

$2,281,947

 

 

$4,577,690

 

 

$2,393,147

 

 

$9,252,784

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Included in the measure of segment assets are:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Addition to non-current assets other than financial instruments and deferred tax assets

 

 

1,382

 

 

 

35,589

 

 

 

-

 

 

 

36,971

 

 

The Company had no inter-segment sales for the periods presented.

 

 
31

Table of Contents

 

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND 2025

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

 

NOTE 17 – SIGNIFICANT EVENTS

 

In July 2025, the Company, through MRNA Scientific Sdn. Bhd., entered into a nonbinding term sheet with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) concerning a proposed strategic cross-equity alliance and exclusive commercialization rights for the VitaGuard™ minimal residual disease (“MRD”) platform in Southeast Asia. On November 28, 2025, the Company completed the Share Subscription and Shareholders’ Agreement with Fidelion and the other parties thereto and entered into an Intellectual Property License Agreement under which the Company obtained exclusive, perpetual commercialization rights for VitaGuard in the ASEAN region. VitaGuard is being developed for liquid-biopsy MRD monitoring. As of September 30, 2026, the platform remained in the commercialization and implementation stage in ASEAN and had not begun generating revenue for the Company.

 

On November 20, 2025, the Company’s Board of Directors adopted the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan (the “Incentive Plan”), which was approved by the Company’s shareholders at the annual meeting held on December 24, 2025. The Incentive Plan initially reserved 472,767 shares of common stock for issuance and provides for annual increases in the share reserve in accordance with its terms. The Incentive Plan reserve for 2026 is 593,632 shares.

 

On May 13, 2026, the Company issued Letters of Demand to the five former officers and directors of Chemrex demanding that the former officers and directors repay to Chemrex the collective sum of approximately $2,944,000 within 14 days. Based on its ongoing investigation, the Company alleges that the former officers and directors caused these amounts to be paid from Chemrex’s corporate accounts during the period from July 2024 through August 2025. The Company alleges that the transactions were unauthorized under Malaysian law; these allegations have not been adjudicated by a court or tribunal. The Company continues to investigate the activities of these parties and their effect on Chemrex. The Company intends to pursue available claims and remedies, as appropriate. As of the date of this report, no court or tribunal proceeding has been commenced in connection with the Letters of Demand.

 

On August 13, 2026, the Company issued an aggregate of 516,128 shares of its common stock, no par value per share, under the Company’s shareholder-approved 2025 Equity Incentive Plan. Each award was a fully vested Other Stock-Based Award under Section 5 of the plan, issued on a bonus basis as compensation for completed services and for no cash consideration. The awards were measured at a grant-date fair value of $1.55 per share, based on the Nasdaq closing price on August 12, 2026, the last closing price before the awards were granted, for an aggregate of $799,998, which was recognized as share-based compensation expense in the three-month period ended September 30, 2026. The awards consisted of 338,709 shares to Su-Leng Tan Lee, the Company’s Chief Executive Officer and President; 96,774 shares to Set Fui Chong, the Company’s Chief Financial Officer and Principal Financial Officer; 32,258 shares to Muhammad Azrul bin Abdul Hamid, an independent director; 32,258 shares to Chee Keong Yap, an independent director; and 16,129 shares to Jook Yuen Low, an independent director. Following the issuances, 77,504 shares remained available under the plan and the Company had 2,933,442 shares of common stock issued and outstanding. The Company relied on Regulation S under the Securities Act of 1933 for the offshore issuances. The shares are restricted securities and remain subject to applicable transfer restrictions.

 

Also on August 13, 2026, the Board reappointed Su-Leng Tan Lee as Chief Executive Officer and President for a fixed term commencing September 1, 2026 and ending August 31, 2029 and approved a new employment agreement effective September 1, 2026. The agreement provides for gross base salary of $35,000 per month, an annual discretionary cash-bonus review with no guaranteed minimum or target, and termination by either party on six months’ written notice, subject to its other terms.

 

NOTE 18 – SUBSEQUENT EVENTS

 

The Company evaluated subsequent events through November 19, 2026, the date these condensed consolidated financial statements were issued.

 

On October 5, 2026, the Company entered into a CogniAI Healthcare Licence and Strategic Collaboration Agreement (the “Agreement”) with Ruanyun Edai Technology Inc., a Cayman Islands company (Nasdaq: RYET) (“RYET”). Under the Agreement, RYET granted the Company and its controlled affiliates an exclusive Malaysian healthcare license to the CogniAI document-intelligence platform, including rights to develop, brand and sublicense applications using it. Exclusivity is subject to any separately signed milestones and applicable cure provisions.

 

On November 13, 2026, the Company closed the Agreement. It issued 410,000 common shares to satisfy the stated US$3.5 million license consideration and a further 150,000 common shares in exchange for 500,000 RYET ordinary shares, as previously reported under Item 3.02 of the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2026. Closing included completion of all share issuances and license activation as provided in the Agreement. The share numbers were fixed, subject to specified capital adjustments, with no cash top-up or market-value guarantee. The contractual license amount is not a statement of fair value. The Company is evaluating the accounting for the transaction.

 

The initial license term is ten years from closing, with two five-year renewal options exercisable on at least six months’ notice if the Company is not then in uncured material breach. RYET will receive a 10% royalty on defined technology receipts actually collected, subject to specified deductions and exclusions, with no minimum royalty or annual platform fee. The Company unilaterally may add other Malaysian industries by notice to RYET. Continued exclusivity in each additional industry will require the Company or an affiliate to sign a customer contract in that industry within twelve months after the notice. Additional work by RYET would require a separate project agreement.

 

 
32

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Description of Business

 

As used herein, unless the context otherwise indicates, references to the “Company,” “we,” “our,” “us,” “BioNexus” refer to BioNexus Gene Lab Corp., a Wyoming company (“BGLC”), and its wholly owned subsidiaries, MRNA Scientific Sdn. Bhd. (“MRNA Scientific Malaysia”), and Chemrex Corporation Sdn. Bhd. (“Chemrex”), both are Malaysian companies.

 

BGLC is an emerging technology company focused on the application of functional genomics to enable early detection of infectious diseases and cancers. On August 23, 2017, we acquired all of the outstanding capital stock of MRNA Scientific Malaysia, which was incorporated in Malaysia on April 7, 2015. MRNA Scientific Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which we use in our business. Our non-invasive blood screening tests analyze changes in ribonucleic acid (or RNA). This blood genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body currently, which was pioneered by BGLC’s founder, Prof. Choong-Chin Liew.

 

The corporate and principal office address of the Company and MRNA Scientific Malaysia is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No. 5 Jln Bangsar Utama 1, Kuala Lumpur, Malaysia. MRNA Scientific’s laboratory is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. MRNA Scientific’s laboratory at Lifecare Diagnostic Centre is temporarily unavailable pending relocation and preparation for the contemplated VitaGuard testing regime and continued cooperation with Fidelion. Our telephone number is (+60) 18-2218762 and our website is www.bionexusgenelab.com.

 

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in ASEAN region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

 

Chemrex’s corporate office and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and website is www.chemrex.com.my.

 

General

 

We were incorporated in the State of Wyoming on May 12, 2017 and operations of our Malaysian company began operations in July 2017. Consequently, the following discussion and analysis of the results of operations and financial condition of the Company is for fiscal periods ended September 30, 2026 and 2025, respectively. This information should be read in conjunction with the consolidated financial statements and notes to the financial statements that are included elsewhere herein. The consolidated financial statements presented herein (and to which this discussion relates) reflect the results of operations of the Company and its Malaysian subsidiaries. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

Overview

 

During the quarter ended September 30, 2026, BioNexus Gene Lab Corp. (“BGLC”, the “Company”, “we”, “us” or “our”) continued to refine its strategic focus across healthcare diagnostics through MRNA Scientific Sdn. Bhd., specialty chemicals through Chemrex Corporation Sdn. Bhd., and its investment and strategic-development activities. Management’s priorities included modernizing and rebuilding the blood-based genomic screening (BGS) platform through GeneMatrix Systems, advancing VitaGuard commercialization planning with Fidelion, stabilizing Chemrex’s core trading operations and collections, and evaluating strategic opportunities under disciplined capital-allocation criteria.

 

These activities remain subject to the technical, regulatory, financing, contractual and operational requirements, uncertainties and risks described in this report.

 

Liquidity Position and Capital Structure

 

As of September 30, 2026, the Company had cash and cash equivalents of $2,223,865 (consisting of bank balances of $865,804, and fixed deposit with original maturities of three months or less of $1,358,061) and total liquidity of $3.4 million. “Total liquidity” is a management liquidity metric comprised of cash and cash equivalents, fixed deposits with original maturities greater than three months, and trade receivables, net. See the Condensed Consolidated Balance Sheets and Note 2 – Summary of Significant Accounting Policies for definitions of cash equivalents and fixed deposits. See also Note 5 – Other Assets and Note 17 – Significant Events for the Fidelion license and other events that may affect capital allocation and future liquidity planning. Management considers these resources and obligations when assessing operating requirements, strategic investments and potential transactions. The Company had no preferred stock, convertible debt or high-yield instruments outstanding as of September 30, 2026. The timing and amount of any capital deployment will depend on the Company’s commitments, liquidity requirements, due diligence and applicable approvals.

 

 
33

Table of Contents

 

The Company continues to evaluate capital-raising alternatives, which may include at-the-market offerings, private placements or strategic financing arrangements, subject to market conditions, corporate authorization, Nasdaq and SEC requirements and the Company’s capital needs.

 

As described in Note 2 to the condensed consolidated financial statements, the Company’s recurring losses and net cash used in operating activities, together with its license payment obligations to Fidelion, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. Management’s plans, which include sales of common stock under the ATM Program with Maxim Group LLC, depend on financing that is not assured and do not alleviate that doubt. Sales under the ATM Program are limited by the Company’s public float under the rules applicable to Form S-3, and there can be no assurance that financing will be available on acceptable terms, or at all.

 

Focus and Development of Core Biotech Business 

 

In July 2025, the Company, through MRNA Scientific Sdn. Bhd., entered into a non‑binding term sheet with Fidelion Diagnostics Pte Ltd (“Fidelion”), a Singapore-based precision diagnostics company specializing in tumor-agnostic, minimal residual disease (MRD) detection. The non-binding term sheet is for a contemplated strategic, cross‑equity alliance and exclusive commercialization rights for the VitaGuard™ MRD platform in Southeast Asia.

 

On November 28, 2025, the Company completed the Share Subscription and Shareholders’ Agreement with Fidelion and the other parties thereto. The Company also entered into an Intellectual Property License Agreement with Fidelion under which the Company obtained exclusive, perpetual commercialization rights for the VitaGuard™ MRD platform in ASEAN. VitaGuard is being developed as a liquid-biopsy platform for MRD monitoring.

 

In January 2026, the Company announced the formal commencement of the deployment phase for VitaGuard. During the quarter ended September 30, 2026, the Company’s activities remained focused on commercialization planning and implementation, including coordination with Fidelion, Tongshu Biotechnology (Hong Kong) Co., Limited (“Tongshu”) and Fidelion’s Chief Commercial Officer, as well as development of regulatory, laboratory and partner arrangements for a proposed rollout in ASEAN. The principal transaction agreements, including the IP and Technology Assignment Agreement between Tongshu and Fidelion (the “IPTA”) and the Company’s License Agreement with Fidelion, have been executed. The Company believes that it and Fidelion are entitled to rely upon the executed agreements in accordance with their terms. Because the transaction documentation and associated intellectual-property and technology packages are extensive and contain numerous representations, warranties, schedules, technical materials and delivery obligations, the parties are continuing customary post-closing review, verification, perfection, recordation, technical-delivery and implementation work. VitaGuard had not begun generating revenue for the Company as of September 30, 2026. The timing and completion of the remaining work are subject to uncertainties.

 

Subsequent to the quarter ended September 30, 2026, MRNA Scientific continued its cooperation with Fidelion. Following the working visit to Tongshu Gene facilities in Shanghai and Changzhou described in the Company’s July 2026 press release, Dr. Muthu Meyyappan, Fidelion’s Chief Commercial Officer, spent approximately three weeks in Malaysia working with MRNA Scientific and other project participants on commercialization planning, laboratory preparation, partner coordination and implementation planning for VitaGuard.

 

During and subsequent to the quarter ended September 30, 2026, MRNA Scientific continued to modernize and rebuild the BGS platform through GeneMatrix Systems. The Company has built an enterprise version of GeneMatrix Systems and has completed internal workflow testing. MRNA Scientific is also developing a new report-presentation system intended to provide secure web and mobile access to screening reports, together with AI-assisted explanatory and companion features. The Company is targeting an initial release, subject to completion of security, privacy, validation, regulatory and management review.

 

Chemrex Corporation Sdn. Bhd. continues to derive substantially all of its revenue from industrial chemical trading. The Board previously authorized management to explore potential contract development and manufacturing organization (“CDMO”) opportunities and related facility, equipment and quality-system requirements. That authorization did not commit the Company to a definitive transition, and management retains discretion to proceed with, modify, partner in or discontinue the initiative based on feasibility, capital requirements, customer demand, regulatory and quality requirements and expected returns.

 

Chemrex’s trading revenue and operations remained severely reduced compared with 2025. Chemrex recorded revenue of $47,917 for the quarter ended September 30, 2026, compared with $75,506 for the quarter ended June 30, 2026, and its gross margin declined to 9.37% from 17.10%. During 2026, Chemrex continued to collect receivables that were outstanding at the beginning of the year, resulting in recoveries of credit losses of $193,847 for the nine-month period. These collections are not recurring trading revenue, and Chemrex remained loss-making for the nine-month period. Management remains focused on rebuilding customer activity, maintaining collection discipline, strengthening credit controls and completing inventory verification.

 

Digital Assets and Treasury Management

 

In March 2025, the Board approved an Ethereum-focused treasury strategy. As of September 30, 2026, the Company held no digital assets and had not committed to acquire any.

 

 
34

Table of Contents

 

Strategic Positioning for Growth and Innovation

 

The Company continues to evaluate strategic partnerships and transactions, including potential mergers, acquisitions and joint ventures. Management’s evaluation considers strategic fit, execution risk, capital requirements, potential contribution to revenue and cash flow, and expected effects on shareholders. Any transaction remains subject to available capital, due diligence, contractual and corporate approvals, applicable law and the risks described in this report.

 

During the quarter, the Company developed an updated corporate website and presentation materials. The updated website was launched in October 2026.

 

Nasdaq Compliance Timeline & Milestones

 

 

·

November 2023: Received an initial Nasdaq compliance notice and began related compliance measures.

 

·

May 2024: Received an initial 180-day compliance extension.

 

·

November 2024: Requested a Nasdaq hearing and received a temporary compliance extension.

 

·

April 2025: Implemented a 1-for-10 reverse stock split.

 

·

April 2025: Nasdaq notified the Company that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.

 

The Company continues to monitor compliance with applicable Nasdaq listing standards as part of its governance and capital-markets activities. Future compliance will depend on continued satisfaction of Nasdaq’s quantitative and qualitative requirements.

 

Recent Developments.

 

(a) Strategic Alliance with Tongshu Biotechnology (Hong Kong) Co., Limited and Fidelion Diagnostics Pte Ltd

 

On November 28, 2025, the Company disclosed the completion of a Share Subscription and Shareholders’ Agreement (the “SSSA”) by and among Fidelion, the Company, Tongshu Biotechnology (Hong Kong) Co., Limited (“Tongshu”), Mr. Su-Leng Tan Lee (the Company’s Chief Executive Officer), Molecule Bio LLC and Rainy Morning Technology (Hong Kong) Limited. The SSSA superseded the July 30, 2025 nonbinding term sheet.

 

Pursuant to the SSSA, Fidelion allotted and issued to the Company 180 Ordinary Shares, representing approximately 15% of Fidelion’s enlarged share capital. In consideration, the Company issued 392,329 shares of its restricted common stock to Fidelion (or approximately 16.6% of the Company’s issued and outstanding common stock).

 

As a condition to completion, the Company and Fidelion also entered into an Intellectual Property License Agreement, pursuant to which the Company obtained exclusive commercial rights to the VitaGuard™ Minimal Residual Disease (MRD) platform in the ASEAN region, on a perpetual and exclusive basis. The license fee is payable over a 24-month instalment schedule.

 

As of September 30, 2026, commercial sales of VitaGuard had not commenced and the Company had not generated revenue from the platform. The current implementation status and dependencies are described under “Focus and Development of Core Biotech Business” above.

 

(b) Internal Controls Enhancement

 

During the reporting period ended September 30, 2026, as a result of prior events and transactions occurring at its Chemrex subsidiary, the Company focused on enhancing its internal control environment and improving governance procedures within its Chemrex subsidiary. Following the internal review of these transactions, management has implemented additional protocols to strengthen compliance with corporate policies and regulatory requirements, particularly concerning related-party transactions and transaction authorization at the subsidiary level.

 

 
35

Table of Contents

 

The Company’s independent registered public accounting firm, JP Centurion & Partners, previously communicated concerns regarding certain aspects of Chemrex’s financial reporting and internal control structure (see Part I, Item 4). These matters were addressed through oversight led by the audit committee, and management has concluded that the Company’s internal control over financial reporting was effective as of September 30, 2026.

   

(c) Filing of Form S-3 Registration Statement.

 

As stated elsewhere herein, on November 7, 2025, the Company filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission to register up to $100 million of securities that may be offered from time to time. The Company concurrently entered into an Equity Distribution Agreement (the “Agreement”) with Maxim Group LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, shares of its common stock, no par value (the “Common Stock”), having an aggregate offering price of up to $20,000,000 through the Agent, acting as the Company’s exclusive sales agent (the “ATM Program”).

 

Sales, if any, will be made in transactions deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, which may be made directly on The Nasdaq Capital Market or otherwise at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices, as permitted by the Agreement. The Company is not obligated to sell any shares under the Agreement, and the Agent is not required to purchase any shares. The Form S-3 became effective on November 27, 2025. As of the date of this report, the Company had sold 53,478 shares under the ATM Program for proceeds of $267,311, all of which were sold in 2025.

 

(d) ARC Group International Equity Purchase Agreement

 

On November 28, 2025, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with ARC Group International Ltd. (“ARC”), the parent of ARC Group Securities, a FINRA registered broker/dealer. Under the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share (“Common Stock”), over a 36-month period (the “Facility”). The purchase price will be at a discount of between 3.0% and 3.5% to the volume-weighted average price of the Common Stock during an agreed pricing period. ARC may not purchase shares under the Facility that would result in its beneficial ownership exceeding 9.99% of the Company’s then outstanding Common Stock and is prohibited from short selling or hedging transactions involving the Company’s securities. Purchases under the Facility require an effective registration statement covering the resale of the shares. As consideration for ARC’s commitment under the Facility, the Company issued to ARC 175,000 shares of Common Stock (the “Commitment Shares”) on November 26, 2025. As of the date of this report, ARC has not purchased any shares under the Purchase Agreement.

 

(e) Transaction with Ruanyun Edai Technology Inc.

 

On October 5, 2026, the Company entered into a CogniAI Healthcare Licence and Strategic Collaboration Agreement (the “Agreement”) with Ruanyun Edai Technology Inc., a Cayman Islands company (Nasdaq: RYET) (“RYET”). Under the Agreement, RYET granted the Company and its controlled affiliates an exclusive Malaysian healthcare license to the CogniAI document-intelligence platform, including rights to develop, brand and sublicense applications using it. Exclusivity is subject to any separately signed milestones and applicable cure provisions.

 

On November 13, 2026, the parties closed the Agreement. The Company issued 410,000 common shares to satisfy the stated US$3.5 million license consideration and a further 150,000 common shares in exchange for 500,000 RYET ordinary shares, as previously reported under Item 3.02 of the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2026. Closing included completion of all share issuances and license activation as provided in the Agreement. The share numbers were fixed, subject to specified capital adjustments, with no cash top-up or market-value guarantee. The contractual license amount is not a statement of fair value.

 

The initial license term is ten years from closing, with two five-year renewal options exercisable on at least six months’ notice if the Company is not then in uncured material breach. RYET will receive a 10% royalty on defined technology receipts actually collected, subject to specified deductions and exclusions, with no minimum royalty or annual platform fee. The Company unilaterally may add other Malaysian industries by notice to RYET. Continued exclusivity in each additional industry will require the Company or an affiliate to sign a customer contract in that industry within twelve months after the notice. Additional work by RYET would require a separate project agreement.

 

Results of Operations

Exchange Rates

 

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Period ended September 30, 2026 /Year-ended December 31, 2025 US$1: MYR exchange rate

 

 

4.080

 

 

 

4.061

 

 

 

 

 

 

 

 

 

 

 

 

January 1,

 

 

January 1,

 

 

 

2026 to

 

 

2025 to

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

Nine-month average US$1: MYR exchange rate

 

 

4.014

 

 

 

4.325

 

 

 
36

Table of Contents

 

Results of Operations for the three and nine-month ended September 30, 2026 compared to the three and nine-month ended September 30, 2025 (unaudited).

 

The following table sets forth key selected financial data for the three-month and nine-month ended September 30, 2026 and 2025.

 

 

 

Three-month periods ended

 

 

Nine-month periods ended

 

Consolidated

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE (Including $nil and $25,649 of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $57,632 of revenue from related parties for the nine-month period ended September 30, 2026 and

2025, respectively)

 

$47,917

 

 

$2,543,823

 

 

$146,915

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period

ended September 30, 2026 and 2025, respectively)

 

 

(43,429)

 

 

(2,166,138)

 

 

(130,235)

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

4,488

 

 

 

377,685

 

 

 

16,680

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

-

 

 

 

4,192

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

16,541

 

 

 

20,778

 

 

 

54,903

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

-

 

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Gain from foreign exchange

 

 

4,402

 

 

 

-

 

 

 

10,065

 

 

 

-

 

Others

 

 

6,239

 

 

 

40,414

 

 

 

22,779

 

 

 

147,231

 

TOTAL OTHER INCOME

 

 

27,182

 

 

 

107,760

 

 

 

87,747

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(35,007)

 

 

(551,569)

 

 

(123,762)

 

 

(1,700,691)

Research and development

 

 

(13,578)

 

 

(14,876)

 

 

(41,736)

 

 

(39,572)

General and administrative (Including $nil and $1,065 of rental expenses to related party for the three month period ended September 30, 2026 and 2025, respectively, and $nil and $3,156 of rental expenses to related party for the nine-month period ended September 30, 2026 and 2025, respectively)

 

 

(311,387)

 

 

(448,791)

 

 

(942,942)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

75,721

 

 

 

(175,818)

 

 

(76,814)

 

 

(121,030)

Share-based compensation

 

 

(799,998)

 

 

-

 

 

 

(799,998)

 

 

-

 

TOTAL OPERATING EXPENSES

 

 

(1,084,249)

 

 

(1,191,054)

 

 

(1,985,252)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,052,579)

 

 

(705,609)

 

 

(1,880,825)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,801)

 

 

(3,382)

 

 

(3,581)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(1,054,380)

 

 

(708,991)

 

 

(1,884,406)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(1,054,380)

 

$(708,991)

 

$(1,884,406)

 

$(1,948,490)

 

 
37

Table of Contents

 

The following tables set forth key selected financial data for the three-month periods ended September 30, 2026 and 2025. 

 

Segmented 

 

Revenue

 

 

 

Three-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

Contribution to total revenue

 

 

2025

 

 

Contribution to total revenue

 

 

Change from prior year

 

 

 

$

 

 

%

 

 

$

 

 

 %

 

 

%

 

MRNA Scientific

 

 

-

 

 

 

-

 

 

 

4,768

 

 

 

0.19

%

 

 

-100

%

Chemrex

 

 

47,917

 

 

 

100.00

%

 

 

2,539,055

 

 

 

99.81

%

 

 

-98.11

%

Total

 

 

47,917

 

 

 

100.00

%

 

 

2,543,823

 

 

 

100.00

%

 

 

-98.12

%

  

Total revenues decreased by 98.12% for the quarter ended September 30, 2026 compared to the same quarter in the prior year, as described below.

 

MRNA Scientific recorded no revenue for the quarter, compared with $4,768 in the same quarter of the prior year, primarily because the laboratory at Lifecare Diagnostic Centre was temporarily unavailable pending relocation and preparation for the contemplated VitaGuard testing regime.

 

Revenue for Chemrex decreased by 98.11% mainly due to lower business volume as a result of the actions of former management which occurred during the course of fiscal year 2025. These actions have negatively impacted the Company’s and Chemrex’s operations and profitability (see Part II, Item 1, Legal Proceedings). Following these actions, the Company has begun transitioning towards a new business model for Chemrex. This model includes expanding into different chemical types and exploring the Contract Development and Manufacturing Organization business. The Company intends to carry out its plans for the change in Chemrex’s operating model and is hopeful that this model will yield improved results in the future.

 

 
38

Table of Contents

 

Cost of Revenues and Gross Margin

 

 

 

Three-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

Contribution to total cost of revenue

 

 

2025

 

 

Contribution to total cost of revenue

 

 

Change from prior year

 

Cost of Revenue

 

$

 

 

 %

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

-

 

 

-

%

 

 

864

 

 

 

0.04%

 

 

-100

%

Chemrex

 

 

43,429

 

 

 

100.00%

 

 

2,165,274

 

 

 

99.96%

 

 

-97.99%

Total

 

 

43,429

 

 

 

100.00%

 

 

2,166,138

 

 

 

100.00%

 

 

-98.00%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MRNA Scientific

 

 

-

 

 

 

 

 

 

 

81.88%

 

 

 

 

 

 

 

 

Chemrex

 

 

9.37%

 

 

 

 

 

 

14.72%

 

 

 

 

 

 

 

 

Total

 

 

9.37%

 

 

 

 

 

 

14.85%

 

 

 

 

 

 

 

 

 

Total cost of revenue decreased by 98.00% for the quarter ended September 30, 2026 compared to the same quarter in the prior year. Cost of revenue for Chemrex decreased by 97.99% to $43,429 from $2,165,274 in the same quarter of the prior year due to the significant reduction in Chemrex revenues. There was no cost of revenue for MRNA Scientific for the quarter due to its lack of revenue.

 

MRNA Scientific had no gross margin for the quarter ended September 30, 2026, as it recorded no revenue.

 

The gross margin percentage for Chemrex is 9.37% during the quarter ended September 30, 2026 compared to same quarter in the previous year of 14.72% mainly due to different mix of products with lower gross margins.

 

Other Income

 

 

 

 

 

Three-month periods ended

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

Other Income

 

2026

 

 

Contribution to total other income

 

 

2025

 

 

Contribution to total other income

 

 

Change from prior year same quarter

 

 

 

$

 

 

%

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

14,893

 

 

 

54.79%

 

 

22,101

 

 

 

20.51%

 

 

-32.61%

Chemrex

 

 

12,287

 

 

 

45.20%

 

 

85,659

 

 

 

79.49%

 

 

-85.66%

BGLC

 

 

2

 

 

 

0.01%

 

 

-

 

 

 

-

 

 

 

-

 

Total

 

 

27,182

 

 

 

100.00%

 

 

107,760

 

 

 

100.00%

 

 

-74.78%

 

Total other income decreased by 74.78% for the quarter ended September 30, 2026 compared to the same quarter in the prior year, as described below. Recoveries of credit losses are now presented within provision for credit losses, net.

 

MRNA Scientific recorded lower other income during the quarter ended September 30, 2026 compared to same quarter in the previous year. Fixed Deposit interest received was lower mainly due to reduction in fixed deposit placement and lower interest rate.

 

Chemrex recorded lower other income during the quarter ended September 30, 2026 compared to the same quarter in the previous year, mainly due to the absence of the gain on disposal of investments in equity securities and dividend income recorded in the prior-year quarter, and lower other income.

 

BGLC recorded other income of $2 during the current quarter primarily due to gain on realized foreign exchange.

 

 
39

Table of Contents

 

Sales and Marketing

 

 

 

Three-month periods ended

 

 

 

September 30,

 

Sales and Marketing

 

2026

 

 

Contribution to total sales and marketing

 

 

2025

 

 

Contribution to total sales and marketing

 

 

Change from prior year same quarter

 

 

 

$

 

 

%

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

31,869

 

 

 

91.04%

 

 

30,211

 

 

 

5.48%

 

5.49

%

Chemrex

 

 

1,650

 

 

 

4.71%

 

 

508,683

 

 

 

92.22%

 

-99.68

%

BGLC

 

 

1,488

 

 

 

4.25%

 

 

12,675

 

 

 

2.30%

 

-88.26

%

Total

 

 

35,007

 

 

 

100.00%

 

 

551,569

 

 

 

100.00%

 

-93.65

%

 

Total sales and marketing expenses decreased by 93.65% for the quarter ended September 30, 2026 compared to the same quarter in the prior year, as described below.

 

Sales and marketing expenses for MRNA Scientific for the quarter ended September 30, 2026 increased by 5.49% mainly due to higher staff expenses compared to same quarter in previous year.

 

Sales and marketing expenses for Chemrex decreased by 99.68% primarily due to lower staff remuneration following the departure of former management and the related reduction in sales staff, as well as lower variable selling expenses.

 

Sales and marketing expenses for the parent, BGLC decreased by 88.26% for the quarter ended September 30, 2026 compared to same quarter in prior year due to lower travelling and business development expenses incurred during the current period.

 

Research and Development

 

 

 

Three-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

Contribution to total research and development

 

 

2025

 

 

Contribution to total research and development

 

 

Change from prior year same quarter

 

 

 

$

 

 

 %

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

13,578

 

 

 

100.00%

 

 

14,876

 

 

 

100.00%

 

 

-8.73%

Total

 

 

13,578

 

 

 

100.00%

 

 

14,876

 

 

 

100.00%

 

 

-8.73%

 

Research and development costs for the quarter ended September 30, 2026 were solely related to MRNA Scientific’s continued development of its blood-based genomic screening (BGS) test. Research and development costs decreased slightly during the current quarter to $13,578 from $14,876 for the same quarter last year.

 

General and Administrative

 

 

 

Three-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

Contribution to total general and administrative

 

 

2025

 

 

Contribution to total general and administrative

 

 

Change from prior year same quarter

 

 

 

$

 

 

%

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

55,835

 

 

 

17.93%

 

 

58,935

 

 

 

13.13%

 

 

-5.26%

Chemrex

 

 

54,787

 

 

 

17.59%

 

 

205,740

 

 

 

45.84%

 

 

-73.37%

BGLC

 

 

200,765

 

 

 

64.47%

 

 

184,116

 

 

 

41.02%

 

 

9.04%

Total

 

 

311,387

 

 

 

100.00%

 

 

448,791

 

 

 

100.00%

 

 

-30.62%

 

Total general and administrative expenses decreased by 30.62% for the quarter ended September 30, 2026 compared to the same quarter in the prior year, as described below. General and administrative expenses for MRNA Scientific decreased by 5.26% during the current quarter compared to the same quarter last year due to lower office expenses and staff costs.

 

General and administrative expenses for Chemrex decreased by 73.37% during the current quarter compared to the same quarter last year primarily due to lower staff salaries and other office expenses.

 

General and administrative expenses for the parent, BGLC increased by 9.04% during the current quarter compared to the same quarter last year due to higher professional fees incurred.

 

 
40

Table of Contents

 

Provision for Credit Losses, Net

 

For the quarter ended September 30, 2026, Chemrex recorded a net reversal of credit losses of $75,721, compared with a provision of $175,818 for the same quarter in the prior year, reflecting collections of receivables that were outstanding at the beginning of the year.

 

Share-based compensation

 

The Company issued an aggregate of 516,128 shares of common stock under the shareholder-approved 2025 Equity Incentive Plan as fully vested Other Stock-Based Awards under Section 5 of that plan for the current quarter ended September 30, 2026. The awards were compensation for completed services and were issued for no cash consideration. The awards were measured at a grant-date fair value of $1.55 per share, based on the Nasdaq closing price on August 12, 2026, the last closing price before the awards were granted, for an aggregate of $799,998.

 

Loss Before Taxes

 

Loss before taxes increased by 48.72% for the current quarter ended September 30, 2026 compared to the same quarter in prior year for the reasons described above.

 

Income Tax Expense

 

For current quarter ended September 30, 2026, we did not have income tax expenses due to our losses incurred.

 

The following tables set forth key selected financial data for the nine-month periods ended September 30, 2026 and 2025. 

 

Segmented 

 

Revenue

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

Contribution to total revenue

 

 

2025

 

 

Contribution to total revenue

 

 

Change from prior year

 

 

 

$

 

 

%

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

1,961

 

 

 

1.33%

 

 

11,302

 

 

 

0.16%

 

 

-82.65%

Chemrex

 

 

144,954

 

 

 

98.67%

 

 

6,929,849

 

 

 

99.84%

 

 

-97.91%

Total

 

 

146,915

 

 

 

100.00%

 

 

6,941,151

 

 

 

100.00%

 

 

-97.88%

 

Total revenues decreased by 97.88% for the nine-month period ended September 30, 2026 compared to the same period in the prior year, as described below.

 

MRNA Scientific’s revenue decreased by 82.65%, primarily attributed to lower sales volume and client referrals from diagnostic centers

 

Revenue for Chemrex decreased by 97.91% mainly due to lower business volume as a result of the actions of former management which occurred during the course of fiscal year 2025. This has negatively impacted Chemrex’s operations and profitability (see Part II, Item 1, Legal Proceedings). Following these actions, the Company has begun transitioning towards a new business model for Chemrex. This model includes expanding into different chemical types and exploring the Contract Development and Manufacturing Organization business. The Company intends to carry out its plans for the change in Chemrex’s operating model and is hopeful that this model will yield improved results in the future.

 

Cost of Revenues and Gross Margin

 

 

 

 

 

 

Nine-month periods ended

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

2026

 

 

Contribution to total cost of revenue

 

 

2025

 

 

Contribution to total cost of revenue

 

 

Change from prior year

 

Cost of Revenue

 

$

 

 

%

 

 

$

 

 

 %

 

 

%

 

MRNA Scientific

 

 

1,250

 

 

 

0.96%

 

 

4,995

 

 

 

0.09%

 

 

-74.97%

Chemrex

 

 

128,985

 

 

 

99.04%

 

 

5,846,956

 

 

 

99.91%

 

 

-97.79%

Total

 

 

130,235

 

 

 

100.00%

 

 

5,851,951

 

 

 

100.00%

 

 

-97.77%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MRNA Scientific

 

 

36.26%

 

 

 

 

 

 

55.80%

 

 

 

 

 

 

 

 

Chemrex

 

 

11.02%

 

 

 

 

 

 

15.63%

 

 

 

 

 

 

 

 

Total

 

 

11.35%

 

 

 

 

 

 

15.69%

 

 

 

 

 

 

 

 

 

Total cost of revenue decreased by 97.77% for the nine-month period ended September 30, 2026 compared to the same period in the prior year. Cost of revenue for Chemrex decreased by 97.79% to $128,985 from $5,846,956 in the same period of the prior year due to the significant reduction in Chemrex revenues.

 

 
41

Table of Contents

 

The gross margin percentage for MRNA Scientific reduced during the nine-month period ended September 30, 2026 compared to same period in the previous year mainly due to a different mix of services with lower gross margins.

 

The gross margin percentage for Chemrex was 11.02% during the nine-month period ended September 30, 2026 compared to same period in the previous year of 15.63%. Lower gross margin was registered mainly due to different mix of products sold with lower gross margins.

 

Other Income

 

 

 

 

 

Nine-month periods ended

 

 

 

 

 

 

 

September 30,

 

 

 

Other Income

 

2026

 

 

Contribution to total other income

 

 

2025

 

 

Contribution to total other income

 

 

Change from prior year same period

 

 

 

$

 

 

%

 

 

$

 

 

 %

 

 

%

 

MRNA Scientific

 

 

46,500

 

 

 

53.00%

 

 

74,565

 

 

 

23.77%

 

 

-37.64%

Chemrex

 

 

41,199

 

 

 

46.95%

 

 

239,164

 

 

 

76.23%

 

 

-82.77%

BGLC

 

 

48

 

 

 

0.05%

 

 

-

 

 

 

-

 

 

 

-

 

Total

 

 

87,747

 

 

 

100.00%

 

 

313,729

 

 

 

100.00%

 

 

-72.03%

 

Total other income decreased by 72.03% for the nine-month period ended September 30, 2026 compared to the same period in the prior year, as described below.

 

Other income for MRNA Scientific reduced by 37.64% during the period ended September 30, 2026 compared to same period in the previous year. Fixed deposit interest received was reduced mainly due to reductions in fixed deposit placement and lower interest rate.

 

Chemrex recorded lower other income during the nine-month period ended September 30, 2026 compared to the same period in the previous year, mainly because dividends, fair value gains and gains on disposal of investments in equity securities were lower following the disposal of its quoted equity securities in 2025, together with lower other income, partly offset by foreign exchange gains.

 

BGLC recorded other income of $48 primarily due to gain on realized foreign exchange.

 

Sales and Marketing

 

 

 

 

 

Nine-month periods ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

Sales and Marketing

 

2026

 

 

Contribution to total sales and marketing

 

 

2025

 

 

Contribution to total sales and marketing

 

 

Change from prior year same period

 

 

 

$

 

 

%

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

98,154

 

 

 

79.31%

 

 

86,275

 

 

 

5.07%

 

 

13.77%

Chemrex

 

 

2,790

 

 

 

2.25%

 

 

1,577,214

 

 

 

92.74%

 

 

-99.82%

BGLC

 

 

22,818

 

 

 

18.44%

 

 

37,202

 

 

 

2.19%

 

 

-38.66%

Total

 

 

123,762

 

 

 

100.00%

 

 

1,700,691

 

 

 

100.00%

 

 

-92.72%

 

Total sales and marketing expenses decreased by 92.72% for the nine-month period ended September 30, 2026 compared to the same period in the prior year, as described below.

 

Sales and marketing expenses for MRNA Scientific for the nine-month period ended September 30, 2026 increased by 13.77% mainly due to higher staff expenses compared to same periods in previous year.

 

Sales and marketing expenses for Chemrex have reduced by 99.82% primarily due to lower staff remuneration following the departure of former management and the related reduction in sales staff, as well as lower variable selling expenses.

 

Sales and marketing expenses for BGLC decreased by 38.66% for the nine-month period ended September 30, 2026, mainly due to lower travelling expenses incurred during the current period.

 

 
42

Table of Contents

 

Research and Development

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

Contribution to total research and development

 

 

2025

 

 

Contribution to total research and development

 

 

Change from prior year same period

 

 

 

$

 

 

 %

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

41,736

 

 

 

100.00%

 

 

39,572

 

 

 

100.00%

 

 

5.47%

Total

 

 

41,736

 

 

 

100.00%

 

 

39,572

 

 

 

100.00%

 

 

5.47%

 

Research and development costs for the nine month period ended September 30, 2026 were solely related to MRNA Scientific’s continued development of its blood-based genomic screening (BGS) test. Research and development costs increased slightly during the current nine-month period to $41,736 from $39,572 for the same period last year.

 

General and Administrative

 

 

 

 

 

Nine-month periods ended

 

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

2026

 

 

Contribution to total general and administrative

 

 

2025

 

 

Contribution to total general and administrative

 

 

Change from prior year same period

 

 

 

$

 

 

%

 

 

$

 

 

%

 

 

%

 

MRNA Scientific

 

 

180,877

 

 

 

19.18%

 

 

270,725

 

 

 

19.85%

 

 

-33.19%

Chemrex

 

 

162,031

 

 

 

17.18%

 

 

492,464

 

 

 

36.10%

 

 

-67.10%

BGLC

 

 

600,034

 

 

 

63.63%

 

 

600,888

 

 

 

44.05%

 

 

-0.14%

Total

 

 

942,942

 

 

 

100.00%

 

 

1,364,077

 

 

 

100.00%

 

 

-30.87%

 

General and Administrative expenses decreased by 30.87% for the nine-month period ended September 30, 2026 compared to same period in the prior year.

 

General and administrative expenses for MRNA Scientific were reduced by 33.19% due to lower office expenses being incurred.

 

General and administrative expenses for Chemrex were reduced by 67.10% primarily due to lower staff salaries and other office expenses.

 

General and administrative expenses for BGLC were slightly reduced by 0.14% due to lower professional and office administrative expenses.

 

Provision for Credit Losses, Net

 

Provision for credit losses, net was $76,814 for the nine-month period ended September 30, 2026, compared with $121,030 for the same period in the prior year. Chemrex recorded provisions of $270,661 based on our assessment of customer payment behavior, partly offset by recoveries of $193,847 from collections of receivables that were outstanding at the beginning of the year.

 

Loss Before Taxes

 

Loss before taxes decreased by 3.29% for the nine-month period ended September 30, 2026 compared to the same period in prior year for the reasons described above.

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

Change from prior year same period

 

 

 

$

 

 

 $

 

 

%

 

MRNA Scientific

 

 

(273,556)

 

 

(315,732)

 

 

-13.36%

Chemrex

 

 

(186,041)

 

 

(994,416)

 

 

-81.29%

BGLC

 

 

(1,424,809)

 

 

(638,342)

 

 

123.20%

Total

 

 

(1,884,406)

 

 

(1,948,490)

 

 

-3.29%

 

Income Tax Expense

 

For the nine-month period ended September 30, 2026, we did not have income tax expenses due to our losses incurred.

 

 
43

Table of Contents

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of September 30, 2026, we had working capital of $3,068,549 compared with working capital of $4,844,448 as of December 31, 2025. The decrease in working capital was due principally to operating losses, unpaid license instalments due to Fidelion and advances from directors.

 

Our primary uses of cash had been for operations and strategic investments. The main sources of cash were generated from operational revenues, the private placement of our common stock, and the proceeds of our public offering. The following trends could result in a material decrease in our liquidity over the near to long term:

 

 

·

Addition of administrative and marketing personnel as the business grows,

 

·

Increases in advertising and marketing in order to attempt to generate more revenues, and

 

·

The cost of being a public company.

 

As described in Note 2 to the condensed consolidated financial statements, there is substantial doubt about the Company’s ability to continue as a going concern.

 

The following is a summary of the Company’s cash flows (used in)/ generated from operating, investing, and financing activities for the nine-month period ended September 30, 2026 and 2025

 

 

 

Nine-month periods ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

$(827,627 )

 

$(2,799,444 )

Net cash generated from investing activities

 

 

389,473

 

 

 

950,468

 

Net cash generated from financing activities

 

 

177,315

 

 

 

32,297

 

Foreign currency translation adjustment

 

 

(1,679 )

 

 

286,805

 

Net change in cash and cash equivalents

 

$(262,518 )

 

$(1,529,874 )

 

Operating Activities

 

During the nine-month period ended September 30, 2026, the Company recorded net cash used in operating activities of $827,627 compared to $2,799,444 for the same period in the prior year. Although the net loss was broadly unchanged, the lower cash outflow reflected non-cash share-based compensation of $799,998, collections of trade receivables, and an increase in other payables, mainly unpaid license instalments due to Fidelion, compared with a significant reduction in trade and other payables in the prior-year period.

 

Investing Activities

 

Cash generated from investing activities was $389,473 for the nine-month period ended September 30, 2026 compared to $950,468 for the same period in the prior year. Cash generated in the nine-month period ended September 30, 2026 was mainly derived from the net decrease in fixed deposits with original maturities of more than three months, partly offset by a down payment of $21,008 for motor vehicles acquired under finance leases and purchases of plant and equipment. In the same period of the previous year, cash was generated mainly from proceeds from disposal of investments in equity securities and dividend income, partly offset by purchases of plant and equipment and an increase in fixed deposits with original maturities of more than three months.

 

Financing Activities

 

Cash generated from financing activities was $177,315 in the nine-month period ended September 30, 2026 compared to $32,297 in the same period of the prior year.

 

The increase in cash generated is primarily attributable to advances from directors.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this item.

 

 
44

Table of Contents

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

As of September 30, 2026, the Company carried out an evaluation under the supervision and with the participation of its Chief Executive Officer and Chief Financial Officer of the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended.

 

Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.

 

Internal Control over Financial Reporting

 

The Company is not required to provide an attestation report from its registered public accounting firm under Section 404(b) of the Sarbanes-Oxley Act of 2002 because it is a non-accelerated filer.

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management reviewed the design and operating effectiveness of the Company’s internal control over financial reporting as of September 30, 2026 and concluded that the Company maintained effective internal control over financial reporting as of that date, and that the material weakness described below has been remediated. Management used the criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

 

Internal Control Remediation at Subsidiary Level

 

During fiscal years 2024 and 2025, respectively, the Company’s independent registered public accounting firm communicated to management a concern regarding the sufficiency of internal financial controls at its Chemrex subsidiary. The identified issues related primarily to documentation standards, delegation of transaction approval authority, and the timeliness of internal reporting.

 

Subsequently, the Company commenced its previously reported remediation plan which targeted the following areas:

 

Remediation Plan

 

 

·

Implementation of a revised delegation of authority policy at the subsidiary level;

 

 

 

 

·

Reconstitution and strengthening of oversight mechanisms through the Board and Audit Committee;

 

 

 

 

·

Review and ratification, if appropriate, of all affected transactions by the Audit Committee;

 

 

 

 

·

Initiation of an internal audit of Chemrex procurement and contracting procedures;

 

 

 

 

·

Staff retraining on internal control and reporting policies.

 

Management has completed the implementation of this remediation plan, including changes in policies, documentation, personnel and delegated authorities, and the Audit Committee has completed its review of the affected transactions. The revised controls have been in operation for a sufficient period of time, and management has concluded, through testing, that these controls were designed and operating effectively as of September 30, 2026. Accordingly, the material weakness has been remediated.

 

Changes in Internal Controls over Financial Reporting

 

During the quarter ended September 30, 2026, the Company completed the remediation measures in response to the material weakness described above, including changes to the approval and oversight processes at the subsidiary level. Other than those remediation activities, there were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2026 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 
45

Table of Contents

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Except as described below, the Company is not a party to any material pending legal proceeding, and no such proceeding is known by the Company to be threatened or contemplated.

 

As previously disclosed, on May 13, 2026, the Company issued Letters of Demand to the five former officers and directors of Chemrex demanding that the former officers and directors repay to Chemrex the collective sum of approximately $2,944,000 within 14 days. Based on its ongoing investigation, the Company alleges that the former officers and directors caused these amounts to be paid from Chemrex’s corporate accounts during the period from July 2024 through August 2025. The Company alleges that the transactions were unauthorized under Malaysian law; these allegations have not been adjudicated by a court or tribunal. The Company continues to investigate the activities of these parties and their effect on Chemrex. The Company intends to pursue available claims and remedies, as appropriate. As of the date of this report, no court or tribunal proceeding has been commenced in connection with the Letters of Demand.

 

Item 1A. Risk Factors.

 

Except as set forth below, there have been no material changes to the risk factors previously disclosed in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The risk factors described in our Form 10-K for the fiscal year ended December 31, 2025, together with the additional risk factors below, should be carefully considered because they could materially affect our business, financial condition and results of operations.

 

Our commercialization of VitaGuard depends on completion of customary post-closing verification, perfection and implementation work, as well as regulatory and operational readiness, and we may not generate revenue from the platform.

 

The principal transaction agreements relating to VitaGuard, including the IPTA between Tongshu and Fidelion and the Company’s License Agreement with Fidelion, have been executed. The Company believes that it and Fidelion are entitled to rely upon the executed agreements in accordance with their terms. The transaction documentation and associated intellectual-property and technology packages are extensive and contain numerous representations, warranties, schedules, technical materials and delivery obligations. The parties are continuing customary post-closing work to review and verify these materials, complete confirmatory assignments and applicable recordations, confirm chain-of-title documentation, and complete delivery and validation of technical documentation, standard operating procedures, software, source code, validation data, manufacturing and quality-control materials and regulatory documentation.

 

Although the Company believes the executed agreements provide a sufficient contractual basis to proceed with commercialization activities, uncertainties remain regarding the timing and completion of this verification, perfection and implementation work. Errors or omissions in transaction schedules, inaccuracies or breaches of representations and warranties, deficiencies in supporting documentation, delays in recordation or delivery, or disagreements regarding contractual obligations could delay regulatory preparation, validation, laboratory readiness or commercial launch; require additional expenditure or remedial documentation; result in disputes or claims; or delay, reduce or prevent revenue from VitaGuard. As of September 30, 2026, the parties were progressing these workstreams, and VitaGuard had not begun generating revenue for the Company. We cannot assure that all remaining work will be completed on the anticipated timetable or that VitaGuard will achieve regulatory acceptance, commercial adoption or profitability.

 

There is substantial doubt about our ability to continue as a going concern.

 

We have incurred recurring losses and net cash outflows from operations, and we have significant license payment obligations to Fidelion. As described in Note 2 to the condensed consolidated financial statements, management has concluded that these conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued, and that our plans, which depend on financing that is not assured, do not alleviate that doubt. If we cannot raise additional capital on acceptable terms, we may be required to reduce or delay our operations or commercialization plans, and our stockholders could lose all or part of their investment. The going concern conclusion may also make it more difficult to raise financing or enter into commercial arrangements.

 

 
46

Table of Contents

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None, other than (i) the issuance on August 13, 2026 of 516,128 shares of common stock under the Company’s 2025 Equity Incentive Plan (“Plan Shares”), which was previously reported in Part II, Item 5 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and (ii) the issuance of 560,000 shares of common stock to Ruanyun Edai Technology Inc. (“RYET Shares”) in connection with the closing of the CogniAI Healthcare Licence and Strategic Collaboration Agreement, which occurred on November 13, 2026. This transaction was previously reported under Item 3.02 of the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2026 and is described under “Issuance of Shares to Ruanyun Edai Technology Inc.” in Item 5 below.

 

The Plan Shares were issued as compensation for completed services. The Plan Shares and the RYET Shares were issued in reliance on Rule 903 of Regulation S under the Securities Act of 1933, as amended. Each recipient represented that the recipient was not a U.S. person, was outside the United States in connection with the offshore issuance and was acquiring the shares for the recipient’s own account and not for the account or benefit of a U.S. person. No directed selling efforts were made in the United States. The shares were issued as restricted securities subject to applicable Regulation S distribution-compliance requirements, restrictive legends and transfer controls.

   

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable to our Company.

 

Item 5. Other Information.

 

Issuance of Shares to Ruanyun Edai Technology Inc.

 

On November 13, 2026, the Company closed the CogniAI Healthcare Licence and Strategic Collaboration Agreement dated October 5, 2026 with Ruanyun Edai Technology Inc. (“RYET”) described in Note 18 to the condensed consolidated financial statements. The Company issued to RYET an aggregate of 560,000 shares of its common stock, no par value per share. Of these shares, 410,000 were issued as the stated US$3.5 million consideration for the exclusive Malaysian healthcare license to the CogniAI platform, and 150,000 were issued in exchange for 500,000 ordinary shares of RYET. The Company received no cash consideration, and no underwriter or placement agent was involved. Following the issuance, the Company had 3,493,442 shares of common stock issued and outstanding. The issuance was previously reported under Item 3.02 of the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2026. Closing included completion of all share issuances and license activation as provided in that agreement.

   

Rule 10b5-1 Trading Arrangements

 

During the three months ended September 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

 
47

Table of Contents

 

Item 6. Exhibits.

 

Exhibit

 

Description

 

 

 

10.1

 

Chief Executive Officer and President Employment Agreement between BioNexus Gene Lab Corp. and Su-Leng Tan Lee, made August 13, 2026 and effective September 1, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026).**

 

 

 

10.2

 

Form of Other Stock-Based Award Agreement and Regulation S Certification, together with the award schedule identifying the five recipients, capacities, share amounts and Board values (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026).**

 

 

 

10.3

 

BioNexus Gene Lab Corp. 2025 Equity Incentive Plan, incorporated by reference to Annex A to the definitive proxy statement filed December 3, 2025 (File No. 001-41750; Accession No. 0001477932-25-008757).**

 

 

 

31.1

 

Certification of the Company’s Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

 

 

 

31.2

 

Certification of the Company’s Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

 

 

 

32.1

 

Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+

 

 

 

32.2

 

Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+

 

 

 

101.INS

 

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).*

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.*

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.*

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.*

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Labels Linkbase Document.*

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.*

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).*

______________

* Filed herewith.

 

** Previously filed or furnished.

 

+ Furnished herewith.

 

 
48

Table of Contents

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

BioNexus Gene Lab Corp.

 

 

/s/ Su-Leng Tan Lee

Su-Leng Tan Lee

 

Chief Executive Officer 

(Principal Executive Officer)

 

 

 

/s/ Set Fui Chong

 

Set Fui Chong

 

Chief Financial Officer 

(Principal Financial and Accounting Officer)

 

 

November 19, 2026

 

 
49

ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

CERTIFICATION

CERTIFICATION

CERTIFICATION

CERTIFICATION

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: R58.htm

IDEA: R59.htm

IDEA: R60.htm

IDEA: R61.htm

IDEA: R62.htm

IDEA: R63.htm

IDEA: R64.htm

IDEA: R65.htm

IDEA: R66.htm

IDEA: R67.htm

IDEA: R68.htm

IDEA: R69.htm

IDEA: R70.htm

IDEA: R71.htm

IDEA: R72.htm

IDEA: R73.htm

IDEA: R74.htm

IDEA: R75.htm

IDEA: R76.htm

IDEA: R77.htm

IDEA: R78.htm

IDEA: R79.htm

IDEA: R80.htm

IDEA: R81.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: bglc_10q_htm.xml